{
 "cells": [
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "# GraphRAG Python\n",
    "End-to-End Example"
   ],
   "id": "cf0be1ddc2bd2434"
  },
  {
   "metadata": {},
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install fsspec langchain-text-splitters openai python-dotenv numpy torch"
   ],
   "id": "9820f541adf30bfd",
   "outputs": [],
   "execution_count": null
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T17:36:45.228870Z",
     "start_time": "2024-10-07T17:36:41.884495Z"
    }
   },
   "cell_type": "code",
   "source": [
    "%%capture\n",
    "%pip install -U git+https://github.com/neo4j/neo4j-graphrag-python"
   ],
   "id": "aa9e401e2305fb0",
   "outputs": [],
   "execution_count": 1
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:45.928472Z",
     "start_time": "2024-10-07T20:45:45.924888Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#%capture\n",
    "#%pip install -U ../demo/neo4j-graphrag-python"
   ],
   "id": "fa8a46520d565af0",
   "outputs": [],
   "execution_count": 1
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:45.936383Z",
     "start_time": "2024-10-07T20:45:45.929580Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "# load neo4j credentials (and openai api key in background)\n",
    "load_dotenv('.env', override=True)\n",
    "NEO4J_URI = os.getenv('NEO4J_URI')\n",
    "NEO4J_USERNAME = os.getenv('NEO4J_USERNAME')\n",
    "NEO4J_PASSWORD = os.getenv('NEO4J_PASSWORD')"
   ],
   "id": "a023c71324bf6e7f",
   "outputs": [],
   "execution_count": 2
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "## KG Building\n",
   "id": "418bd212bae7f492"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:48.741391Z",
     "start_time": "2024-10-07T20:45:48.043236Z"
    }
   },
   "cell_type": "code",
   "source": [
    "import neo4j\n",
    "from neo4j_graphrag.experimental.components.embedder import TextChunkEmbedder\n",
    "from neo4j_graphrag.llm import OpenAILLM\n",
    "from neo4j_graphrag.embeddings.openai import OpenAIEmbeddings\n",
    "\n",
    "driver = neo4j.GraphDatabase.driver(NEO4J_URI, auth=(NEO4J_USERNAME, NEO4J_PASSWORD))\n",
    "\n",
    "extractor_llm=OpenAILLM(\n",
    "    model_name=\"gpt-4o-mini\",\n",
    "    model_params={\n",
    "        \"response_format\": {\"type\": \"json_object\"}, # use json_object formatting for best results\n",
    "        \"temperature\": 0 # turning temperature down for more deterministic results\n",
    "    }\n",
    ")\n",
    "\n",
    "#create text embedder\n",
    "embedder = OpenAIEmbeddings()"
   ],
   "id": "fd60a2f512b9701d",
   "outputs": [],
   "execution_count": 3
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:49.389867Z",
     "start_time": "2024-10-07T20:45:49.385286Z"
    }
   },
   "cell_type": "code",
   "source": [
    "#define node labels\n",
    "basic_node_labels = [\"Object\",\n",
    "                     \"Entity\",\n",
    "                     \"Group\",\n",
    "                     \"Person\",\n",
    "                     \"Organization\",\n",
    "                     \"Place\"]\n",
    "\n",
    "academic_node_labels = [\"ArticleOrPaper\",\n",
    "                        \"PublicationOrJournal\"]\n",
    "\n",
    "medical_node_labels = [\"Anatomy\",\n",
    "                       \"BiologicalProcess\",\n",
    "                       \"Cell\",\n",
    "                       \"CellularComponent\",\n",
    "                       \"CellType\",\n",
    "                       \"Condition\",\n",
    "                       \"Disease\",\n",
    "                       \"Drug\",\n",
    "                       \"EffectOrPhenotype\",\n",
    "                       \"Exposure\",\n",
    "                       \"GeneOrProtein\",\n",
    "                       \"Molecule\",\n",
    "                       \"MolecularFunction\",\n",
    "                       \"Pathway\"]\n",
    "\n",
    "node_labels = basic_node_labels + academic_node_labels + medical_node_labels\n",
    "\n",
    "# define relationship types\n",
    "rel_types = [\"ACTIVATES\",\n",
    "             \"AFFECTS\",\n",
    "             \"ASSESSES\",\n",
    "             \"ASSOCIATED_WITH\",\n",
    "             \"AUTHORED\",\n",
    "             \"CAUSES\",\n",
    "             \"CITES\",\n",
    "             \"CLASSIFIES\",\n",
    "             \"COLLABORATES_WITH\"\n",
    "             \"CONTRIBUTES_TO\",\n",
    "             \"CORRELATES_WITH\",\n",
    "             \"DESCRIBES\",\n",
    "             \"DEVELOPED\",\n",
    "             \"DISCUSSES\",\n",
    "             \"EXHIBITS\",\n",
    "             \"EXPRESSES\",\n",
    "             \"HAS_EFFECT\",\n",
    "             \"HAS_SYMPTOM\",\n",
    "             \"INCLUDES\",\n",
    "             \"INDUCES\",\n",
    "             \"INTERACTS_WITH\",\n",
    "             \"INVOLVES\",\n",
    "             \"LEADS_TO\",\n",
    "             \"LINKED_TO\",\n",
    "             \"LOCATED_IN\",\n",
    "             \"MANIFESTS_AS\",\n",
    "             \"OBSERVED_IN\",\n",
    "             \"PARTICIPATES_IN\",\n",
    "             \"PART_OF\",\n",
    "             \"PRODUCES\",\n",
    "             \"PUBLISHED_IN\",\n",
    "             \"REACTS_WITH\",\n",
    "             \"REDUCES\",\n",
    "             \"RELATED_TO\",\n",
    "             \"RESULTS_IN\",\n",
    "             \"TARGETS\",\n",
    "             \"TREATMENT_FOR\",\n",
    "             \"TRIGGERS\",\n",
    "             \"USED_FOR\",\n",
    "             \"USED_WITH\",\n",
    "             \"USES\"]\n"
   ],
   "id": "6cba83fa4638e21d",
   "outputs": [],
   "execution_count": 4
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:56.877620Z",
     "start_time": "2024-10-07T20:45:56.874599Z"
    }
   },
   "cell_type": "code",
   "source": [
    "prompt_template = '''\n",
    "You are a medical researcher tasks with extracting information from papers \n",
    "and structuring it in a property graph to inform further medical and research Q&A\n",
    "\n",
    "Extract the entities (nodes) and specify their type from the following Input text.\n",
    "Also extract the relationships between these nodes. the relationship direction goes from the start node to the end node. \n",
    "\n",
    "\n",
    "Return result as JSON using the following format:\n",
    "{{\"nodes\": [ {{\"id\": \"0\", \"label\": \"the type of entity\", \"properties\": {{\"name\": \"name of entity\", \"details\":\" brief description of entity (dont include info about relationships)\" }} }}],\n",
    "  \"relationships\": [{{\"type\": \"TYPE_OF_RELATIONSHIP\", \"start_node_id\": \"0\", \"end_node_id\": \"1\", \"properties\": {{\"details\": \"brief description of relationship if needed\"}} }}] }}\n",
    "\n",
    "- Use only the information from the Input text.  Do not add any additional information.  \n",
    "- If the input text is empty, return empty Json. \n",
    "- Make sure to create as many nodes and relationships as needed to offer rich medical context for further research.\n",
    "- An AI knowledge assistant must be able to read this graph and immediately understand the context to inform detailed research questions. \n",
    "- Multiple documents will be ingested from different sources and we are using this property graph to connect information, so make sure entity types are fairly general. \n",
    "\n",
    "Use only fhe following nodes and relationships (if provided):\n",
    "{schema}\n",
    "\n",
    "Assign a unique ID (string) to each node, and reuse it to define relationships.\n",
    "Do respect the source and target node types for relationship and\n",
    "the relationship direction.\n",
    "\n",
    "Do not return any additional information other than the JSON in it.\n",
    "\n",
    "Examples:\n",
    "{examples}\n",
    "\n",
    "Input text:\n",
    "\n",
    "{text}\n",
    "'''"
   ],
   "id": "8cbcdedcd1757b1d",
   "outputs": [],
   "execution_count": 5
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:45:58.094024Z",
     "start_time": "2024-10-07T20:45:57.771170Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from langchain_text_splitters import CharacterTextSplitter\n",
    "from neo4j_graphrag.experimental.components.text_splitters.langchain import LangChainTextSplitterAdapter\n",
    "from neo4j_graphrag.experimental.pipeline.kg_builder import SimpleKGPipeline\n",
    "\n",
    "kg_builder_pdf = SimpleKGPipeline(\n",
    "    llm=extractor_llm,\n",
    "    driver=driver,\n",
    "    embedder=embedder,\n",
    "    entities=node_labels,\n",
    "    relations=rel_types,\n",
    "    prompt_template=prompt_template,\n",
    "    #text_splitter=LangChainTextSplitterAdapter(CharacterTextSplitter(chunk_size=500, chunk_overlap=100, separator=\".\")),\n",
    "    from_pdf=True\n",
    ")"
   ],
   "id": "94e1dfac980e6527",
   "outputs": [],
   "execution_count": 6
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:51:00.406683Z",
     "start_time": "2024-10-07T20:48:32.469757Z"
    }
   },
   "cell_type": "code",
   "source": [
    "pdf_file_paths = ['truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf', \n",
    "             'truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf', \n",
    "             'truncated-pdfs/pgpm-13-39-trunc.pdf']\n",
    "\n",
    "for path in pdf_file_paths:\n",
    "    print(f\"Processing : {path}\")\n",
    "    pdf_result = await kg_builder_pdf.run_async(file_path=path)\n",
    "    print(f\"PDF Processing Result: {pdf_result}\")"
   ],
   "id": "edeee98826a970a8",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Processing : truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (n, row) { ... }} {position: line: 1, column: 168, offset: 167} for query: 'UNWIND $rows AS row CREATE (n:__KGBuilder__ {id: row.id}) SET n += row.properties WITH n, row CALL apoc.create.addLabels(n, row.labels) YIELD node WITH node as n, row CALL { WITH n, row WITH n, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setNodeVectorProperty(n, emb, row.embedding_properties[emb]) RETURN count(*) as nbEmb } RETURN elementId(n)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PDF Processing Result: run_id='59d8838f-2032-40e9-9362-6fe145384700' result={'resolver': {'number_of_nodes_to_resolve': 117, 'number_of_created_nodes': 110}}\n",
      "Processing : truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (n, row) { ... }} {position: line: 1, column: 168, offset: 167} for query: 'UNWIND $rows AS row CREATE (n:__KGBuilder__ {id: row.id}) SET n += row.properties WITH n, row CALL apoc.create.addLabels(n, row.labels) YIELD node WITH node as n, row CALL { WITH n, row WITH n, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setNodeVectorProperty(n, emb, row.embedding_properties[emb]) RETURN count(*) as nbEmb } RETURN elementId(n)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PDF Processing Result: run_id='3263a97b-861b-4fb1-be8b-13bd22f77244' result={'resolver': {'number_of_nodes_to_resolve': 194, 'number_of_created_nodes': 179}}\n",
      "Processing : truncated-pdfs/pgpm-13-39-trunc.pdf\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (n, row) { ... }} {position: line: 1, column: 168, offset: 167} for query: 'UNWIND $rows AS row CREATE (n:__KGBuilder__ {id: row.id}) SET n += row.properties WITH n, row CALL apoc.create.addLabels(n, row.labels) YIELD node WITH node as n, row CALL { WITH n, row WITH n, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setNodeVectorProperty(n, emb, row.embedding_properties[emb]) RETURN count(*) as nbEmb } RETURN elementId(n)'\n",
      "Received notification from DBMS server: {severity: WARNING} {code: Neo.ClientNotification.Statement.FeatureDeprecationWarning} {category: DEPRECATION} {title: This feature is deprecated and will be removed in future versions.} {description: CALL subquery without a variable scope clause is now deprecated. Use CALL (rel, row) { ... }} {position: line: 1, column: 254, offset: 253} for query: 'UNWIND $rows as row MATCH (start:__KGBuilder__ {id: row.start_node_id}) MATCH (end:__KGBuilder__ {id: row.end_node_id}) WITH start, end, row CALL apoc.merge.relationship(start, row.type, {}, row.properties, end, row.properties) YIELD rel  WITH rel, row CALL { WITH rel, row WITH rel, row WHERE row.embedding_properties IS NOT NULL UNWIND keys(row.embedding_properties) as emb CALL db.create.setRelationshipVectorProperty(rel, emb, row.embedding_properties[emb]) } RETURN elementId(rel)'\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "PDF Processing Result: run_id='df3a182b-a2f0-4429-837c-f7a4449976df' result={'resolver': {'number_of_nodes_to_resolve': 303, 'number_of_created_nodes': 273}}\n"
     ]
    }
   ],
   "execution_count": 8
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## KG Retrieval\n",
    "Now lets make some knowledge graph retrievers which we will later use for a GraphRAG pipeline"
   ],
   "id": "a9c0fd965b15b143"
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "We will leverage Neo4j's vector search capabilities here. To do this we need to begin by creating a vector index on the text in our Chunk nodes",
   "id": "4d7b98e310104246"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:55:17.097173Z",
     "start_time": "2024-10-07T20:55:16.437252Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.indexes import create_vector_index\n",
    "\n",
    "create_vector_index(driver, name=\"text_embeddings\", label=\"Chunk\", embedding_property=\"embedding\", dimensions=1536, similarity_fn=\"cosine\")"
   ],
   "id": "940b051107b89204",
   "outputs": [
    {
     "ename": "Neo4jIndexError",
     "evalue": "Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.",
     "output_type": "error",
     "traceback": [
      "\u001B[0;31m---------------------------------------------------------------------------\u001B[0m",
      "\u001B[0;31mClientError\u001B[0m                               Traceback (most recent call last)",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:112\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    111\u001B[0m     logger\u001B[38;5;241m.\u001B[39minfo(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mCreating vector index named \u001B[39m\u001B[38;5;124m'\u001B[39m\u001B[38;5;132;01m{\u001B[39;00mname\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m'\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n\u001B[0;32m--> 112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:959\u001B[0m, in \u001B[0;36mDriver.execute_query\u001B[0;34m(self, query_, parameters_, routing_, database_, impersonated_user_, bookmark_manager_, auth_, result_transformer_, **kwargs)\u001B[0m\n\u001B[1;32m    958\u001B[0m \u001B[38;5;28;01mwith\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_pipelined_begin:\n\u001B[0;32m--> 959\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m session\u001B[38;5;241m.\u001B[39m_run_transaction(\n\u001B[1;32m    960\u001B[0m         access_mode, TelemetryAPI\u001B[38;5;241m.\u001B[39mDRIVER,\n\u001B[1;32m    961\u001B[0m         work, (query_str, parameters, result_transformer_), {}\n\u001B[1;32m    962\u001B[0m     )\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/session.py:554\u001B[0m, in \u001B[0;36mSession._run_transaction\u001B[0;34m(self, access_mode, api, transaction_function, args, kwargs)\u001B[0m\n\u001B[1;32m    553\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 554\u001B[0m     result \u001B[38;5;241m=\u001B[39m transaction_function(tx, \u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    555\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m asyncio\u001B[38;5;241m.\u001B[39mCancelledError:\n\u001B[1;32m    556\u001B[0m     \u001B[38;5;66;03m# if cancellation callback has not been called yet:\u001B[39;00m\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/driver.py:1290\u001B[0m, in \u001B[0;36m_work\u001B[0;34m(tx, query, parameters, transformer)\u001B[0m\n\u001B[1;32m   1284\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_work\u001B[39m(\n\u001B[1;32m   1285\u001B[0m     tx: ManagedTransaction,\n\u001B[1;32m   1286\u001B[0m     query: te\u001B[38;5;241m.\u001B[39mLiteralString,\n\u001B[1;32m   1287\u001B[0m     parameters: t\u001B[38;5;241m.\u001B[39mDict[\u001B[38;5;28mstr\u001B[39m, t\u001B[38;5;241m.\u001B[39mAny],\n\u001B[1;32m   1288\u001B[0m     transformer: t\u001B[38;5;241m.\u001B[39mCallable[[Result], t\u001B[38;5;241m.\u001B[39mUnion[_T]]\n\u001B[1;32m   1289\u001B[0m ) \u001B[38;5;241m-\u001B[39m\u001B[38;5;241m>\u001B[39m _T:\n\u001B[0;32m-> 1290\u001B[0m     res \u001B[38;5;241m=\u001B[39m tx\u001B[38;5;241m.\u001B[39mrun(query, parameters)\n\u001B[1;32m   1291\u001B[0m     \u001B[38;5;28;01mreturn\u001B[39;00m transformer(res)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/transaction.py:172\u001B[0m, in \u001B[0;36mTransactionBase.run\u001B[0;34m(self, query, parameters, **kwparameters)\u001B[0m\n\u001B[1;32m    171\u001B[0m parameters \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mdict\u001B[39m(parameters \u001B[38;5;129;01mor\u001B[39;00m {}, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwparameters)\n\u001B[0;32m--> 172\u001B[0m result\u001B[38;5;241m.\u001B[39m_tx_ready_run(query, parameters)\n\u001B[1;32m    174\u001B[0m \u001B[38;5;28;01mreturn\u001B[39;00m result\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:171\u001B[0m, in \u001B[0;36mResult._tx_ready_run\u001B[0;34m(self, query, parameters)\u001B[0m\n\u001B[1;32m    167\u001B[0m \u001B[38;5;28;01mdef\u001B[39;00m \u001B[38;5;21m_tx_ready_run\u001B[39m(\u001B[38;5;28mself\u001B[39m, query, parameters):\n\u001B[1;32m    168\u001B[0m     \u001B[38;5;66;03m# BEGIN+RUN does not carry any extra on the RUN message.\u001B[39;00m\n\u001B[1;32m    169\u001B[0m     \u001B[38;5;66;03m# BEGIN {extra}\u001B[39;00m\n\u001B[1;32m    170\u001B[0m     \u001B[38;5;66;03m# RUN \"query\" {parameters} {extra}\u001B[39;00m\n\u001B[0;32m--> 171\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_run(query, parameters, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m, \u001B[38;5;28;01mNone\u001B[39;00m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:221\u001B[0m, in \u001B[0;36mResult._run\u001B[0;34m(self, query, parameters, db, imp_user, access_mode, bookmarks, notifications_min_severity, notifications_disabled_classifications)\u001B[0m\n\u001B[1;32m    220\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39msend_all()\n\u001B[0;32m--> 221\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attach()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/work/result.py:409\u001B[0m, in \u001B[0;36mResult._attach\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    408\u001B[0m \u001B[38;5;28;01mwhile\u001B[39;00m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_attached \u001B[38;5;129;01mis\u001B[39;00m \u001B[38;5;28;01mFalse\u001B[39;00m:\n\u001B[0;32m--> 409\u001B[0m     \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_connection\u001B[38;5;241m.\u001B[39mfetch_message()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:178\u001B[0m, in \u001B[0;36mConnectionErrorHandler.__getattr__.<locals>.outer.<locals>.inner\u001B[0;34m(*args, **kwargs)\u001B[0m\n\u001B[1;32m    177\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 178\u001B[0m     func(\u001B[38;5;241m*\u001B[39margs, \u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mkwargs)\n\u001B[1;32m    179\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (Neo4jError, ServiceUnavailable, SessionExpired) \u001B[38;5;28;01mas\u001B[39;00m exc:\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt.py:860\u001B[0m, in \u001B[0;36mBolt.fetch_message\u001B[0;34m(self)\u001B[0m\n\u001B[1;32m    857\u001B[0m tag, fields \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39minbox\u001B[38;5;241m.\u001B[39mpop(\n\u001B[1;32m    858\u001B[0m     hydration_hooks\u001B[38;5;241m=\u001B[39m\u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39mresponses[\u001B[38;5;241m0\u001B[39m]\u001B[38;5;241m.\u001B[39mhydration_hooks\n\u001B[1;32m    859\u001B[0m )\n\u001B[0;32m--> 860\u001B[0m res \u001B[38;5;241m=\u001B[39m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39m_process_message(tag, fields)\n\u001B[1;32m    861\u001B[0m \u001B[38;5;28mself\u001B[39m\u001B[38;5;241m.\u001B[39midle_since \u001B[38;5;241m=\u001B[39m monotonic()\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_bolt5.py:370\u001B[0m, in \u001B[0;36mBolt5x0._process_message\u001B[0;34m(self, tag, fields)\u001B[0m\n\u001B[1;32m    369\u001B[0m \u001B[38;5;28;01mtry\u001B[39;00m:\n\u001B[0;32m--> 370\u001B[0m     response\u001B[38;5;241m.\u001B[39mon_failure(summary_metadata \u001B[38;5;129;01mor\u001B[39;00m {})\n\u001B[1;32m    371\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m (ServiceUnavailable, DatabaseUnavailable):\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j/_sync/io/_common.py:245\u001B[0m, in \u001B[0;36mResponse.on_failure\u001B[0;34m(self, metadata)\u001B[0m\n\u001B[1;32m    244\u001B[0m Util\u001B[38;5;241m.\u001B[39mcallback(handler)\n\u001B[0;32m--> 245\u001B[0m \u001B[38;5;28;01mraise\u001B[39;00m Neo4jError\u001B[38;5;241m.\u001B[39mhydrate(\u001B[38;5;241m*\u001B[39m\u001B[38;5;241m*\u001B[39mmetadata)\n",
      "\u001B[0;31mClientError\u001B[0m: {code: Neo.ClientError.Schema.EquivalentSchemaRuleAlreadyExists} {message: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'.}",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m                           Traceback (most recent call last)",
      "Cell \u001B[0;32mIn[9], line 3\u001B[0m\n\u001B[1;32m      1\u001B[0m \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01mneo4j_graphrag\u001B[39;00m\u001B[38;5;21;01m.\u001B[39;00m\u001B[38;5;21;01mindexes\u001B[39;00m \u001B[38;5;28;01mimport\u001B[39;00m create_vector_index\n\u001B[0;32m----> 3\u001B[0m create_vector_index(driver, name\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mtext_embeddings\u001B[39m\u001B[38;5;124m\"\u001B[39m, label\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mChunk\u001B[39m\u001B[38;5;124m\"\u001B[39m, embedding_property\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124membedding\u001B[39m\u001B[38;5;124m\"\u001B[39m, dimensions\u001B[38;5;241m=\u001B[39m\u001B[38;5;241m1536\u001B[39m, similarity_fn\u001B[38;5;241m=\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mcosine\u001B[39m\u001B[38;5;124m\"\u001B[39m)\n",
      "File \u001B[0;32m~/opt/anaconda3/envs/neo4j-graphrag-python-example/lib/python3.11/site-packages/neo4j_graphrag/indexes.py:118\u001B[0m, in \u001B[0;36mcreate_vector_index\u001B[0;34m(driver, name, label, embedding_property, dimensions, similarity_fn, neo4j_database)\u001B[0m\n\u001B[1;32m    112\u001B[0m     driver\u001B[38;5;241m.\u001B[39mexecute_query(\n\u001B[1;32m    113\u001B[0m         query,\n\u001B[1;32m    114\u001B[0m         {\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mname\u001B[39m\u001B[38;5;124m\"\u001B[39m: name, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mdimensions\u001B[39m\u001B[38;5;124m\"\u001B[39m: dimensions, \u001B[38;5;124m\"\u001B[39m\u001B[38;5;124msimilarity_fn\u001B[39m\u001B[38;5;124m\"\u001B[39m: similarity_fn},\n\u001B[1;32m    115\u001B[0m         database_\u001B[38;5;241m=\u001B[39mneo4j_database,\n\u001B[1;32m    116\u001B[0m     )\n\u001B[1;32m    117\u001B[0m \u001B[38;5;28;01mexcept\u001B[39;00m neo4j\u001B[38;5;241m.\u001B[39mexceptions\u001B[38;5;241m.\u001B[39mClientError \u001B[38;5;28;01mas\u001B[39;00m e:\n\u001B[0;32m--> 118\u001B[0m     \u001B[38;5;28;01mraise\u001B[39;00m Neo4jIndexError(\u001B[38;5;124mf\u001B[39m\u001B[38;5;124m\"\u001B[39m\u001B[38;5;124mNeo4j vector index creation failed: \u001B[39m\u001B[38;5;132;01m{\u001B[39;00me\u001B[38;5;241m.\u001B[39mmessage\u001B[38;5;132;01m}\u001B[39;00m\u001B[38;5;124m\"\u001B[39m) \u001B[38;5;28;01mfrom\u001B[39;00m \u001B[38;5;21;01me\u001B[39;00m\n",
      "\u001B[0;31mNeo4jIndexError\u001B[0m: Neo4j vector index creation failed: An equivalent index already exists, 'Index( id=3, name='text_embeddings', type='VECTOR', schema=(:Chunk {embedding}), indexProvider='vector-2.0' )'."
     ]
    }
   ],
   "execution_count": 9
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now that the index is set up we will start simple with a VectorRetriever.  The VectorRetriever just queries Chunk nodes, brining back the text and some metadata",
   "id": "ec95391c989ee694"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:55:19.364482Z",
     "start_time": "2024-10-07T20:55:19.037891Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorRetriever\n",
    "\n",
    "from neo4j_graphrag.embeddings.openai import OpenAIEmbeddings\n",
    "\n",
    "embedder = OpenAIEmbeddings()\n",
    "\n",
    "vector_retriever = VectorRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    return_properties=[\"text\"],\n",
    ")"
   ],
   "id": "eeda7e519c60a02b",
   "outputs": [],
   "execution_count": 10
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:55:20.576812Z",
     "start_time": "2024-10-07T20:55:20.063686Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vector_res = vector_retriever.get_search_results(query_text = \"Which biomarkers are associated with predicting organ damage in lupus patients?\")\n",
    "\n",
    "for i in vector_res.records: print(\"====\\n\" + i.data()['node']['text'])"
   ],
   "id": "ca27731a1f99d71d",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "lar\n",
      "adhesion molecules 1; VGLL-3: vestigial-like family member 3.\n",
      "5.1. Biomarkers in Lupus Nephritis (LN)\n",
      "Renal biopsy is the gold standard for diagnosing, classifying, and prognosing LN.\n",
      "However, it cannot be widely employed due to certain disadvantages, including it being\n",
      "an intrinsically invasive procedure, the risk of bleeding, and the possibility of sampling\n",
      "error [ 87]. Furthermore, a 10% to 20% misclassiﬁcation risk may occur when conducting\n",
      "a ﬁne needle percutaneous renal biopsy because of the possibility of not being able to\n",
      "penetrate the pathological location of renal or pathological error analysis [ 88]. In addition,\n",
      "serial biopsies cannot be conducted due to the invasive nature and potential complications\n",
      "associated with the procedure [ 89,90]. For these reasons, routine renal biopsy has been\n",
      "considered controversial and a question has been raised about whether it is absolutely\n",
      "required to diagnose LN [91].\n",
      "5.1.1. Serum Anti-dsDNA Antibodies\n",
      "Anti-dsDNA antibodies are biomarkers that are associated with SLE disease activ-\n",
      "ity [50,51], and they can predict the development of LN [ 51]. The level of anti-dsDNA\n",
      "antibodies can ﬂuctuate over time [ 92] because of their association with SLE disease activ-\n",
      "ity [38,93]. They can disappear during treatment and return during a ﬂare, especially in\n",
      "active nephritis [ 94]. As one of the most characteristic ANA types, anti-dsDNA antibodies\n",
      "have a high speciﬁcity (96%) but low diagnostic sensitivity (52–70%) for SLE because of\n",
      "their transient appearance [18,52].\n",
      "IIF using Crithidialuciliae as a substrate and ELISA are the most common assays for\n",
      "anti-dsDNA detection. The level of anti-dsDNA antibodies does not always correlate with\n",
      "active LN, and this makes anti-dsDNA an unreliable biomarker for assessing disease\n",
      "activity [ 92]. Although anti-dsDNA antibodies can exacerbate LN by being deposited in the\n",
      "kidney or driving cytokine production, the levels of anti-DNA antibodies do not necessarily\n",
      "correlate with active disease [ 92]. The reasons for anti-dsDNA antibody level variability\n",
      "may be the following: (1) antibody concentration varies with the SLE pathology over time,\n",
      "(2) antibodies may be deposited in renal tissue and not detectable in serum, (3) assays\n",
      "for anti-dsDNA antibodies are not sensitive and speciﬁc enough, (4) non-nephritic ﬂares\n",
      "are not always accompanied by anti-dsDNA antibodies [ 95], and (5) not all subclasses\n",
      "of anti-dsDNA antibodies are pathogenic and associated with disease activity and renal\n",
      "disease [92,96].\n",
      "Biomolecules 2021 ,11, 928 8 of 16\n",
      "5.1.2. Serum Anti-SmAntibody\n",
      "Presence of anti-Sm antibodies is included in SLE classiﬁcation criteria and serves\n",
      "as a biomarker for SLE classiﬁcation [ 18,20]. Anti-Sm antibodies are characteristic of\n",
      "SLE and have not been detected in other rheumatic diseases or in healthy individuals.\n",
      "Anti-Sm antibodies are correlated with SLE disease activity and are a highly speciﬁc\n",
      "diagnostic biomarker for SLE with a speciﬁcity of 99% but have a low sensitivity of\n",
      "5–30% [1,18,26,53,54]. Moreover, anti-Sm antibodies are associated with LN, and their\n",
      "presence in patients with SLE indicates that LN may be acquired in the future [ 55,56]. In\n",
      "addition, high titers of anti-Sm antibodies were identiﬁed as predictor of silent LN [ 57] and\n",
      "may predict early poor outcomes in LN [56].\n",
      "5.1.3. Anti-C1q Antibodies\n",
      "Hereditary C1q deﬁciency is strongly associated with SLE [ 97]. Anti-C1q antibodies\n",
      "result in decreased C1q, which may play a pathogenic role in the development of LN\n",
      "by inhibiting clearance of immune complexes and apoptotic bodies or by depositing\n",
      "immune complexes to the glomerular basement membrane [ 98,99]. Increased anti-C1q\n",
      "antibody titers predict renal ﬂares in LN with an 81% to 97% sensitivity and a 71% to 95%\n",
      "speciﬁcity [ 58,59]. Moreover, anti-C1q titers are correlated with active LN, and the absence\n",
      "of anti-C1q is associated with a nearly 100% negative predictive value for the development\n",
      "of LN [ 60]. These reports suggest that an\n",
      "====\n",
      "EBiomarkers Sample Type Key Points Refs\n",
      "Lupus nephritisAnti-dsDNA antibodies SerumAssociated with SLE disease activity and can\n",
      "predict the development of LN; high\n",
      "speciﬁcity (96%), low diagnostic sensitivity\n",
      "(52–70%).[18,50–52]\n",
      "Anti-Sm antibodies SerumCorrelates with SLE disease activity and LN;\n",
      "highly speciﬁc diagnostic biomarker for SLE\n",
      "with a speciﬁcity of 99% but with a low\n",
      "sensitivity of 5–30%; high titers of anti-Sm\n",
      "antibodies predict silent LN; predict early\n",
      "poor outcomes in LN.[1,18,26,53–57]\n",
      "Anti-C1q antibodies SerumIncreased anti-C1q antibody titers predict\n",
      "renal ﬂares in LN with an 81–97% sensitivity\n",
      "and a 71% to 95% speciﬁcity; anti-C1q\n",
      "titerscorrelates with active LN, and the\n",
      "absence of anti-C1q is associated with a\n",
      "nearly 100% negative predictive value for the\n",
      "development of LN; Standardized laboratory\n",
      "assay has not been established.[58–61]\n",
      "Proteinuria;\n",
      "Protein/creatinine ratio;\n",
      "24-h urine proteinUrineConventional urinary biomarkers for LN.\n",
      "Spot urine protein/creatinine ratio is not\n",
      "always reliable estimate of 24-h proteinuria.[62,63]\n",
      "Chemokines (MCP-1, IL-8,\n",
      "RANTES, IP-10, CXCL-16);\n",
      "Cytokines (TGF- β,\n",
      "IL-17,uTWEAK,\n",
      "adiponectin, IL-6,\n",
      "osteoprotegerin);\n",
      "Adhesionmolecules\n",
      "(VCAM-1, ICAM-1)UrineEvaluated as potential SLE biomarkers, but\n",
      "few of them have been independently\n",
      "validated.[64–66]\n",
      "Angiopoetin-like 4;\n",
      "L-selectin; TGF- β1UrineBiomarker candidates for tracking disease\n",
      "activity in LN.[67]\n",
      "Skin lesionsAhR ratio SerumAssociated with SLE activity and may be an\n",
      "independent risk factor for skin lesions in\n",
      "SLE.[68]\n",
      "Anti-SSA antibodies Serum Associated with subacute cutaneous lupus. [69]\n",
      "VGLL-3 Serum Leads to cutaneous lupus. [70]\n",
      "NPSLELupus anticoagulant\n",
      "antibodies;\n",
      "Anticardiolipin antibodies;\n",
      "Anti-β2-glycoprotein I\n",
      "antibodiesSerum or CSFAssociated with NPSLE manifestations;\n",
      "diagnostic biomarkers of NPSLE and used to\n",
      "make treatment decisions.[71,72]\n",
      "Anti-RibP Serum or CSFHighly speciﬁc biomarker in the diagnosis of\n",
      "SLE and associated with NPSLE.[73]\n",
      "Anti-U1 ribonucleoprotein\n",
      "antibodiesSerum or CSFElevated in CSF and sera of NPSLE patients;\n",
      "might cause NPSLE.[74,75]\n",
      "Anti-NMDAR CSFAssociated with central nervous system\n",
      "manifestations of NPSLE.[76,77]\n",
      "IL-6, 8, 10, TNF-a; IFN- γ;\n",
      "MCP-1; IP-10CSF Associated with NPSLE. [78,79]\n",
      "Biomolecules 2021 ,11, 928 7 of 16\n",
      "Table 2. Cont.\n",
      "Organ-Speciﬁc\n",
      "Damage in SLEBiomarkers Sample Type Key Points Refs\n",
      "CVDLHR; MHR SerumPredicts CVD risk in SLE patients, even at the\n",
      "onset of disease.[80]\n",
      "Cardiac troponin T SerumIndependently associated with incident\n",
      "cardiovascular events in SLE patients.[81,82]\n",
      "Paraoxonase 1 and HDL SerumKey biomarker of accelerated atherosclerosis\n",
      "in lupus and may serve as a potential\n",
      "therapeutic biomarker for SLE patients with\n",
      "CVD; early biomarkers of endothelial\n",
      "damage and premature atherosclerosis in\n",
      "SLE; therapeutic targets for preventing CVD\n",
      "in SLE patients.[83,84]\n",
      "IgG-anticardiolipin\n",
      "antibodies; E-selectinSerumAssociated with CVD in SLE and correlated\n",
      "with disease activity.[85,86]\n",
      "AhR ratio: the ratio of aryl hydrocarbon receptor in Th17 cells to that in Treg; Anti-NMDAR: N-methyl-D-aspartate receptor; CSF:\n",
      "cerebrospinal ﬂuid; CVD: cardiovascular disease; CXCL-16: C-X-C motif chemokine 16; HDL: high-density lipoprotein; ICAM-1: intracel-\n",
      "lular adhesion molecule1; IL: interleukin; IP-10: interferon[IFN]- γ-inducible protein 10; LHR: low-density granulocytes-to-high-density\n",
      "lipoprotein cholesterol ratio; MCP-1: monocyte chemoattractant protein-1; MHR: monocyte-to-high-density lipoprotein cholesterol ratio;\n",
      "NPSLE: neuropsychiatric systemic lupus erythematosus; RANTES: regulated upon activation, normal T-cell expressed and secreted; TGF- β:\n",
      "transforming growth factor-beta; uTWEAK: urinary tumor necrosis factor [TNF]-like weak inducer of apoptosis; VCAM-1: vascular cellular\n",
      "adhesion molecules 1; VGLL-3: vestigial-like family member 3.\n",
      "5.1. Biomarkers in Lupus Nephritis (LN)\n",
      "Renal biopsy is the gold standard for diagnosing, classifying, and prognosing LN.\n",
      "However, it \n",
      "====\n",
      "er, anti-C1q titers are correlated with active LN, and the absence\n",
      "of anti-C1q is associated with a nearly 100% negative predictive value for the development\n",
      "of LN [ 60]. These reports suggest that anti-C1q antibodies may serve as a non-invasive\n",
      "biomarker for predicting renal ﬂares. Unfortunately, anti-C1q antibodies have not been\n",
      "included in SLE classiﬁcation criteria or for the clinical management of SLE because they\n",
      "lack a standardized laboratory assay [ 61]. In addition, anti-C1q antibodies can be found in\n",
      "other autoimmune diseases, including hypocomplementemic urticarial vasculitis (100%),\n",
      "Sjögren’s syndrome (26%), rheumatoid arthritis (19%), and Stevens-Johnson syndrome\n",
      "(14%), and even in apparently healthy individuals (3–5%) [61,98].\n",
      "5.1.4. Other Urinary Biomarkers\n",
      "Urine is an easily and non-invasively obtainable biological sample and it directly\n",
      "reﬂects pathological changes in kidneys [ 68]. Hence, urinary biomarkers seem to be more\n",
      "promising than serum biomarkers. Proteinuria, protein/creatinine ratio in spot urine,\n",
      "and 24-h urine protein are conventional urinary biomarkers for LN. However, spot urine\n",
      "protein/creatinine ratio is not always a reliable estimate of 24-h proteinuria [ 62,63]. There-\n",
      "fore, new urinary biomarkers have been investigated. Various urine protein candidate\n",
      "biomarkers, including chemokines (monocyte chemoattractant protein-1, RANTES, inter-\n",
      "feron [IFN]- γ-inducible protein 10 (IP-10), C-X-C motif chemokine 16, and interleukin-8),\n",
      "cytokines (urinary tumor necrosis factor [TNF]-like weak inducer of apoptosis, interleukin-\n",
      "17, interleukin-6, adiponectin, transforming growth factor-beta, and osteoprotegerin [ 64]),\n",
      "growth factors, adhesion molecules (vascular cellular adhesion molecules 1 [ 65], and intra-\n",
      "cellular adhesion molecule1 [ 66]) have been evaluated as potential SLE biomarkers, but few\n",
      "of them have been independently validated. Moreover, urine angiopoetin-like 4, L-selectin,\n",
      "and TGF- β1 are biomarker candidates for tracking disease activity in LN [ 67]. A few points\n",
      "to note regarding urinary biomarkers include that their concentration can vary daily, their\n",
      "measurement could be affected by urinary infections—which should be ruled out, and\n",
      "they may not be speciﬁc for a particular disease since most inﬂammatory diseases share\n",
      "common molecular pathways [68].\n",
      "5.2. Biomarkers for Skin Lesions in SLE\n",
      "Skin lesions are typical clinical manifestations of SLE, and only a few biomarkers can\n",
      "be used for them. Our previous study reported that the ratio of aryl hydrocarbon receptor\n",
      "in Th17 cells to that in Treg (AhR ratio) is associated with SLE activity, and this ratio may\n",
      "be an independent risk factor for skin lesions in SLE [ 68]. Moreover, anti-SSA antibodies\n",
      "are associated with subacute cutaneous lupus [ 69]. The skin-targeted overexpression of\n",
      "Biomolecules 2021 ,11, 928 9 of 16\n",
      "vestigial-like family member 3 drives a proinﬂammatory gene expression program that\n",
      "leads to cutaneous lupus [70].\n",
      "5.3. Biomarkers in Neuropsychiatric SLE (NPSLE)\n",
      "NPSLE is one of the severe complications of lupus, which affects the central and pe-\n",
      "ripheral nervous systems. Biomarkers for NPSLE are obtained from serum or cerebrospinal\n",
      "ﬂuid (CSF) [ 71]. Antiphospholipid antibodies, including lupus anticoagulant, anticar-\n",
      "diolipin, and anti- β2-glycoprotein I antibodies, are detected in serum and/or CSF are\n",
      "associated with NPSLE manifestations [ 71,72]. They are diagnostic biomarkers of NPSLE\n",
      "and used to make treatment decisions [ 71]. Moreover, the presence of antibodies against\n",
      "N-methyl-D-aspartate receptor (anti-NMDAR) in CSF are associated with central-nervous-\n",
      "system manifestations of NPSLE, such as an acute confusional state, anxiety disorders,\n",
      "cognitive dysfunctions, mood disorders, and psychosis, and it may distinguish patients\n",
      "with central NPSLE from peripheral NPSLE [ 76,77]. The level of serum anti-NMDAR is\n",
      "higher in patients with NPSLE than in SLE patients without NPSLE [ 77]. Antibodies against\n",
      "ribosomal proteins (\n",
      "====\n",
      "ents\n",
      "with central NPSLE from peripheral NPSLE [ 76,77]. The level of serum anti-NMDAR is\n",
      "higher in patients with NPSLE than in SLE patients without NPSLE [ 77]. Antibodies against\n",
      "ribosomal proteins (anti-RibP) are a highly speciﬁc biomarker for diagnosing SLE and are\n",
      "associated with NPSLE [ 73]. The variability of anti-RibP test results from different assays\n",
      "and diagnostic platforms is the main challenge for its clinical use [ 73]. ELISA, immunodif-\n",
      "fusion, and immunoblot are the main methods used to detect anti-RibP , and all of them\n",
      "have signiﬁcant heterogeneity [73].\n",
      "Increased levels of immunological biomarkers in CSF, such as interleukin-6, interleukin-\n",
      "8, interleukin-10, TNF-a, IFN- γ, monocyte chemoattractant protein-1, and IP-10 were as-\n",
      "sociated with NPSLE [ 78,79]. Anti-U1 ribonucleoprotein antibodies were elevated in the\n",
      "CSF and sera of NPSLE patients [ 74], and they might cause NPSLE by inducing neurotoxic\n",
      "inﬂammatory mediators in the sheath [75].\n",
      "5.4. Biomarkers for Cardiovascular Involvement in SLE\n",
      "Cardiovascular disease (CVD) is one of the most important complications of SLE, and\n",
      "it is an important factor causing morbidity and mortality. The monocyte-to-high-density\n",
      "lipoprotein cholesterol ratio and low-density granulocytes-to-high-density lipoprotein\n",
      "cholesterol ratio are high in SLE patients with atheromatosis but not in CVD-free patients,\n",
      "and thus they are biomarkers for identifying CVD risk in SLE patients, even at the onset\n",
      "of disease [ 80]. Moreover, dysfunctional high-density lipoprotein is a key biomarker of\n",
      "accelerated atherosclerosis in lupus and may serve as a potential therapeutic biomarker\n",
      "for SLE patients with CVD [ 83]. High sensitivity of serum cardiac troponin T was the\n",
      "ﬁrst identiﬁed biomarker that was independently associated with incident cardiovascular\n",
      "events in SLE patients [ 81,82]. Serum levels of antibodies against paraoxonase 1 and high-\n",
      "density lipoprotein are potential early biomarkers of endothelial damage and premature\n",
      "atherosclerosis in SLE, and thus they are useful therapeutic targets for preventing CVD\n",
      "in SLE patients [ 84]. In addition, serum levels of IgG-anticardiolipin antibodies [ 85] and\n",
      "E-selectin [86] are associated with CVD in lupus and correlated with disease activity.\n",
      "6. Omics Approaches in SLE\n",
      "Omics approaches provide opportunities for revealing new biomarkers for SLE to\n",
      "track the disease course with greater sensitivity and speciﬁcity. Omics, including the\n",
      "transcriptome (mRNA and single-cell), epigenome, genome, and metabolome, have been\n",
      "extensively used to gain insight into SLE [100–102].\n",
      "6.1. Transcriptome in SLE\n",
      "An integrative analysis of publicly available multi-omics data from the T cells, B cells,\n",
      "and peripheral blood cells of SLE patients demonstrated that 18 transcription factors were\n",
      "signiﬁcantly enriched in all three types of cells [ 103]. The most prominent of them were\n",
      "related to type I IFN signaling, such as STAT1 and STAT2, which are two essential com-\n",
      "ponents of the IFN-stimulated gene factor 3 complex and can bind to the IFN-stimulated\n",
      "Biomolecules 2021 ,11, 928 10 of 16\n",
      "response element (ISRE) in the promoters of IFN-stimulated genes (ISGs) [ 103]. A single-\n",
      "cell transcriptomic analysis of renal stromal cells of LN patients demonstrated that the\n",
      "IFN and ﬁbrosis characteristics of tubule cells might be associated with poorer response\n",
      "to therapy [ 104]. Using single-cell RNA sequencing, Nehar-Belaid et al. reported that an\n",
      "increased level of ISGs can distinguish cells from children with SLE from cells of healthy\n",
      "controls, and the high levels of ISGs are derived from transcriptionally deﬁned subpopula-\n",
      "tions within major cell types, including monocytes, CD4+and CD8+T cells, natural killer\n",
      "cells, dendritic cells, B cells, and especially plasma cells. Subpopulations of enriched ISGs\n",
      "and/or monogenic lupus-associated genes can classify SLE activity [ 105]. Single-cell RNA\n",
      "sequencing was also used to analyze kidney samples from patients with LN, and it was\n",
      "f\n",
      "====\n",
      "biomolecules\n",
      "Review\n",
      "Clinical and Immunological Biomarkers for Systemic\n",
      "Lupus Erythematosus\n",
      "Haitao Yu1,*, Yasuo Nagafuchi2,3,*\n",
      "and Keishi Fujio2\n",
      "/gid00030/gid00035/gid00032/gid00030/gid00038/gid00001/gid00033/gid00042/gid00045 /gid00001\n",
      "/gid00048/gid00043/gid00031/gid00028/gid00047/gid00032/gid00046\n",
      "Citation: Yu, H.; Nagafuchi, Y.;\n",
      "Fujio, K. Clinical and Immunological\n",
      "Biomarkers for Systemic Lupus\n",
      "Erythematosus. Biomolecules 2021 ,11,\n",
      "928. https://doi.org/10.3390/\n",
      "biom11070928\n",
      "Academic Editor: Carlo Perricone\n",
      "Received: 19 May 2021\n",
      "Accepted: 17 June 2021\n",
      "Published: 22 June 2021\n",
      "Publisher’s Note: MDPI stays neutral\n",
      "with regard to jurisdictional claims in\n",
      "published maps and institutional afﬁl-\n",
      "iations.\n",
      "Copyright: © 2021 by the authors.\n",
      "Licensee MDPI, Basel, Switzerland.\n",
      "This article is an open access article\n",
      "distributed under the terms and\n",
      "conditions of the Creative Commons\n",
      "Attribution (CC BY) license (https://\n",
      "creativecommons.org/licenses/by/\n",
      "4.0/).1Department of Laboratory Medicine, The First Hospital of Lanzhou University, Lanzhou University,\n",
      "Lanzhou 730000, China\n",
      "2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo,\n",
      "Tokyo 113-8655, Japan; FUJIOK-INT@h.u-tokyo.ac.jp\n",
      "3Department of Functional Genomics and Immunological Disease, Graduate School of Medicine,\n",
      "The University of Tokyo, Tokyo 113-8655, Japan\n",
      "*Correspondence: yuhaitao7707@163.com (H.Y.); nagafuchi@g.ecc.u-tokyo.ac.jp (Y.N.);\n",
      "Tel.: +86-0931-8356-241 (H.Y.); +81-3-3815-5411 (Y.N.)\n",
      "Abstract: Systemic lupus erythematosus (SLE) is characterized by immune system dysfunction and\n",
      "is clinically heterogeneous, exhibiting renal, dermatological, neuropsychiatric, and cardiovascular\n",
      "symptoms. Clinical and physiological assessment is usually inadequate for diagnosing and assessing\n",
      "pathophysiological processes in SLE. Clinical and immunological biomarkers could play a critical\n",
      "role in improving diagnosis, assessment, and ultimately, control of SLE. This article reviews clinical\n",
      "and immunological biomarkers that could diagnose and monitor disease activity in SLE, with and\n",
      "without organ-speciﬁc injury. In addition, novel SLE biomarkers that have been discovered through\n",
      "“omics” research are also reviewed.\n",
      "Keywords: systemic lupus erythematosus; biomarkers; diagnosis; monitoring; omics\n",
      "1. Introduction\n",
      "Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized\n",
      "by aberrant activity of the immune system [ 1] and presents with a wide range of clinical\n",
      "manifestations, including renal, dermatological, neuropsychiatric, and cardiovascular symp-\n",
      "toms [ 2]. The incidence of SLE is 0.3–31.5 in 100,000 per year, and the adjusted prevalence\n",
      "is approaching, or even exceeding, 50–100 in 100,000 [ 3]. Unfortunately, there appears to\n",
      "be a trend of increasing SLE prevalence with time [ 4]. Healthcare-related costs of SLE are\n",
      "related to disease severity and the types of organ(s) involved [ 5]. Patients with SLE had\n",
      "mean annual costs of about $21,000–$53,000 in the USA [ 6], and their mean annual direct\n",
      "medical cost was €2600– €4800 in Europe [7].\n",
      "SLE is an important social and public health problem, as the medication and mul-\n",
      "tidisciplinary approach for treating SLE can only control the symptoms and delay the\n",
      "progression of the disease but cannot cure it completely [ 1]. It is critical to improve the\n",
      "ability to diagnose SLE early for effective treatment. Therefore, biomarkers, especially\n",
      "immunological biomarkers, have emerged to help better diagnose SLE and assess its patho-\n",
      "physiological processes, with the ultimate goal of improving control of the disease. The\n",
      "aim of the current study was to review immunological biomarkers for SLE diagnosis and\n",
      "pathophysiological process assessment.\n",
      "2. Characteristics of Biomarkers\n",
      "A biomarker is deﬁned as a measurable indicator of a normal biological process, a\n",
      "pathogenic process, or a response to drug exposure or intervention [ 8]. Recently, biomarkers\n",
      "were redeﬁned such that they must have a speciﬁc phys\n"
     ]
    }
   ],
   "execution_count": 11
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "The GraphRAG Python Package offers a whole host of other useful retrieval covering different GraphRAG patterns (text2cypher, vector and/or full text + Cypher template, etc.).  and if none of those fit perfectly you can implement your own custom retrievers. \n",
    "\n",
    "Below we will use the VectorCypherRetriever which allows you to run a graph traversal after finding text chunks.  We will use the Cypher Query language to define the logic to traverse the graph.  \n",
    "\n",
    "As a simple starting point, lets traverse up to 2 hops out from each chunk and textualize the different relationships we pick up.  We will use something called a quantified path pattern to accomplish in this. "
   ],
   "id": "2b2ee3da2339365f"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:55:28.763355Z",
     "start_time": "2024-10-07T20:55:28.507847Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.retrievers import VectorCypherRetriever\n",
    "\n",
    "vc_retriever=VectorCypherRetriever(\n",
    "    driver,\n",
    "    index_name=\"text_embeddings\",\n",
    "    embedder=embedder,\n",
    "    retrieval_query=\"\"\"\n",
    "MATCH (node)<-[:FROM_CHUNK]-()-[rl:!FROM_CHUNK]-{1,2}()\n",
    "UNWIND rl AS r\n",
    "WITH DISTINCT r\n",
    "MATCH (sourceDoc:Document)<-[FROM_DOCUMENT]-()<-[:FROM_CHUNK]-(n)-[r]->(m)\n",
    "WITH n,r,m, apoc.text.join(collect(DISTINCT sourceDoc.path), ', ') AS sources\n",
    "// return textualize relations\n",
    "RETURN n.name + '(' + coalesce(n.details, '') + ')'+ \n",
    "    ' - ' + type(r) + '(' + coalesce(r.details, '') + ')' +  ' -> ' + \n",
    "    m.name + '(' + coalesce(m.details, '') + ')' + ' [sourced from: ' + sources + ']' AS fact\n",
    "        \"\"\",\n",
    ")\n"
   ],
   "id": "caf84995e4bc8d4",
   "outputs": [],
   "execution_count": 12
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:55:31.055031Z",
     "start_time": "2024-10-07T20:55:30.378725Z"
    }
   },
   "cell_type": "code",
   "source": [
    "vc_res = vc_retriever.get_search_results(query_text = \"How do environmental factors influence systemic lupus erythematosus?\")\n",
    "for i in vc_res.records: print(\"====\\n\" + i.data()['fact']) "
   ],
   "id": "4a1df583f2450f35",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====\n",
      "Environmental factors, toxicants and systemic lupus erythematosus(A paper discussing the impact of environmental factors and toxicants on systemic lupus erythematosus.) - DESCRIBES(The paper discusses environmental factors affecting systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "SLE: another autoimmune disorder influenced by microbes and diet?(A paper investigating the influence of microbes and diet on systemic lupus erythematosus.) - DESCRIBES(The paper investigates the influence of diet and microbes on systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Derivation and validation of the systemic lupus erythematosus international collaborating clinics classification criteria(A study on the classification criteria for systemic lupus erythematosus.) - DESCRIBES(The study presents classification criteria for systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus(A paper detailing the classification criteria for systemic lupus erythematosus.) - DESCRIBES(The paper outlines the classification criteria for systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Validation of new systemic lupus erythematosus classification criteria(A study validating new classification criteria for systemic lupus erythematosus.) - DESCRIBES(The study validates new classification criteria for systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "The role of stress in the mosaic of autoimmunity: an overlooked association(A paper exploring the association between stress and autoimmunity.) - DESCRIBES(The paper explores the association between stress and systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus(A paper updating the classification criteria for systemic lupus erythematosus.) - DESCRIBES(The paper updates the classification criteria for systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Sex hormones in acquired immunity and autoimmune disease(A paper discussing the role of sex hormones in immunity and autoimmune diseases.) - DESCRIBES(The paper discusses systemic lupus erythematosus in relation to sex hormones.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms(A review discussing the interaction between viruses and autoimmune responses.) - DESCRIBES(The review discusses the potential interactions between viruses and systemic lupus erythematosus.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Cigarette smoking and the risk of systemic lupus erythematosus(A study examining the relationship between smoking and the risk of developing systemic lupus erythematosus.) - DESCRIBES(The study examines the risk factors for systemic lupus erythematosus related to smoking.) -> Systemic lupus erythematosus(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Granzyme B(A protein associated with poor prognosis in lupus nephritis.) - HAS_EFFECT(Granzyme B levels are correlated with poor prognosis in lupus nephritis.) -> Nephritis(Inflammation of the kidneys, often associated with SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - HAS_SYMPTOM(Nephritis is a common symptom of SLE.) -> Nephritis(Inflammation of the kidneys, often associated with SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(T cells are also central to the pathophysiology of SLE.) -> T cells(A type of lymphocyte involved in the immune response.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(B cells are central to the pathophysiology of SLE.) -> B cells(A type of lymphocyte that produces antibodies.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(GWAS have been important for identifying genetic risk loci for SLE.) -> Genome-wide association studies (GWAS)(Research studies that identify genetic variants associated with diseases.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(Dendritic cells are involved in the immune response related to SLE.) -> Dendritic Cells (DC)(Antigen presenting cells that play a role in the immune response.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(Neutrophils are involved in the pathophysiology of SLE.) -> Neutrophils(A type of immune cell involved in the pathophysiology of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(Plasmacytoid dendritic cells produce type 1 interferon in response to nucleic acids in SLE.) -> Plasmacytoid Dendritic Cells (pDC)(A subset of dendritic cells that produce type 1 interferon in response to nucleic acids.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(Epigenetic alterations play a key role in the pathogenesis of SLE.) -> Epigenetic alterations(Changes in gene expression regulation that can influence disease pathogenesis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - ASSOCIATED_WITH(Metabolome analysis is used to identify biomarkers for SLE.) -> Metabolome analysis(Study of metabolites in biological samples to identify potential biomarkers.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "ITGAM(A susceptibility gene for lupus nephritis.) - ASSOCIATED_WITH(ITGAM is identified as a susceptibility gene for lupus nephritis.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - TREATMENT_FOR(Belimumab is used to treat SLE by targeting B cells.) -> Belimumab(A drug that targets B cells through BLyS/BAFF blockage.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - TREATMENT_FOR(Rituximab is used for B cell depletion in SLE patients.) -> Rituximab(A second-line treatment used in severe cases of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - MANIFESTS_AS(Lupus nephritis is a significant complication of SLE.) -> Lupus Nephritis(A severe manifestation of SLE characterized by inflammation of the kidneys.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - INCLUDES(SLE is diagnosed based on clinical symptoms.) -> Clinical Symptoms(Symptoms and signs used to diagnose and classify SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - INCLUDES(SLE classification includes laboratory biomarkers.) -> Laboratory Biomarkers(Biomarkers that reflect immune reactivity and inflammation in SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Complement(A part of the immune system that enhances the ability to clear pathogens.) - PARTICIPATES_IN(The complement system participates in the immune response in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "C1q(A complement molecule linked to lupus-like diseases.) - LINKED_TO(C1q deficiency is linked to lupus-like diseases.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) - HAS_EFFECT(SLE is characterized by the production of autoantibodies.) -> Autoantibodies(Antibodies that mistakenly target and react with a person's own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "IFI44L(A gene whose methylation level is a diagnostic marker for SLE.) - HAS_EFFECT(Methylation of the IFI44L promoter serves as a diagnostic marker for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "L-valine(An amino acid identified as a potential diagnostic biomarker for SLE.) - HAS_EFFECT(L-valine is identified as a potential diagnostic biomarker for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Reactive Oxygen Species (ROS)(Molecules that may contribute to SLE pathogenesis.) - AFFECTS(Reactive oxygen species may contribute to the pathogenesis of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Immunologic Criteria(Criteria used to assess the immunological basis of SLE.) - PART_OF(Immunologic criteria are part of the assessment for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by systemic inflammation and a variety of clinical manifestations.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(Nephritis is a common symptom of SLE.) -> Nephritis(Inflammation of the kidneys, often associated with SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Azizoddin(A researcher who demonstrated the predictive value of the Physical Functioning domain of SF-36 in SLE.) - AUTHORED(Azizoddin demonstrated the predictive value of the Physical Functioning domain of SF-36 in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Lindblom(A researcher who performed a post-hoc analysis of data from BLISS-52 and BLISS-76 studies.) - AUTHORED(Lindblom performed a post-hoc analysis related to SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(DNA methylation is linked to the pathogenesis of SLE.) -> DNA Methylation(A process by which methyl groups are added to DNA, affecting gene expression.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(Sjogren's syndrome is often associated with SLE.) -> Sjogren's Syndrome(An autoimmune disease that often occurs alongside SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSOCIATED_WITH(Fibromyalgia can co-occur with SLE.) -> Fibromyalgia(A condition that can co-occur with SLE and influence patient-physician discordance.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Anti-Nucleosome Antibodies (ANuA)(Antibodies that can be used in diagnosing SLE and drug-induced lupus.) - ASSOCIATED_WITH(ANuA is related to SLE and its disease activity.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Anti-dsDNA antibodies(Biomarkers associated with SLE disease activity and lupus nephritis.) - ASSOCIATED_WITH(Anti-dsDNA antibodies are associated with SLE disease activity.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Belimumab is used in the treatment of SLE.) -> Belimumab(A drug that targets B cells through BLyS/BAFF blockage.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Cyclophosphamide is used for severe life-threatening lupus.) -> Cyclophosphamide(A chemotherapy drug that is also used as an immunosuppressant.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - TREATMENT_FOR(Rituximab is used in the treatment of SLE.) -> Rituximab(A second-line treatment used in severe cases of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Antimalarials(Medications shown to be beneficial in most SLE patients.) - TREATMENT_FOR(Antimalarials are used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Glucocorticoids (GC)(A class of steroid hormones used in the treatment of SLE.) - TREATMENT_FOR(Glucocorticoids are used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Immunosuppressants (IS)(Medications that suppress or reduce the strength of the body's immune system.) - TREATMENT_FOR(Immunosuppressants are used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - INVOLVES(Immunosuppression is a key process involved in managing SLE.) -> Immunosuppression(A process aimed at controlling the disease while minimizing susceptibility to infections.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - INVOLVES(SLE involves an imbalance in the apoptosis process.) -> Apoptosis(A process of programmed cell death that is crucial for maintaining health by eliminating old cells.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - ASSESSES(Disease activity is assessed in patients with SLE.) -> Disease Activity(The level of activity in SLE that needs to be accurately defined.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Patient Reported Outcomes (PROs)(Tools used to measure patients' perceptions of their health status.) - ASSESSES(PROs are used to assess health-related quality of life in SLE patients.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "British Isles Lupus Assessment Group (BILAG)(A scoring system that provides a comprehensive approach to managing patients with lupus.) - ASSESSES(BILAG scoring system assesses disease activity in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Biomarkers(Biological molecules that indicate the presence or severity of a disease.) - ASSESSES(Biomarkers are used to assess SLE patients.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Antinuclear Antibody (ANA) Testing(A laboratory test used to detect the presence of antinuclear antibodies in the serum.) - ASSESSES(ANA testing is used to assess eligibility for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Physicians(Medical professionals who treat patients with SLE and assess disease activity.) - ASSESSES(Physicians assess the condition of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - INCLUDES(Gut microbiota is affected in patients with SLE.) -> Gut Microbiota(The community of microorganisms living in the digestive tracts of humans and other animals.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "CD4+ T cells(A type of immune cell that plays a significant role in the immune response.) - PARTICIPATES_IN(CD4+ T cells are involved in the immune response in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Integrate project(A European project focused on integrating patient-driven data into the management of SLE.) - PARTICIPATES_IN(The Integrate project focuses on the management of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Patients(Individuals diagnosed with SLE who experience various symptoms and challenges.) - PARTICIPATES_IN(Patients are diagnosed with SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_EFFECT(SLE has a high sensitivity for ANA tests.) -> Sensitivity of ANA Tests(The ability of ANA tests to correctly identify patients with SLE, reported to be between 90% to 95%.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_EFFECT(SLE has a relatively low specificity for ANA tests.) -> Specificity of ANA Tests(The ability of ANA tests to correctly identify healthy individuals, which is relatively low.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Erythrocyte Sedimentation Rate (ESR)(A key sign of inflammation in SLE used for monitoring disease activity.) - HAS_EFFECT(High ESR values are a key sign of inflammation in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "C-Reactive Protein (CRP)(A biomarker that can indicate inflammation and is used in conjunction with ESR.) - HAS_EFFECT(Low CRP levels can indicate inflammation in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Patient-Reported Outcomes (PROs)(Measures that capture the patient's perspective on their health status.) - HAS_EFFECT(Patient-Reported Outcomes (PROs) are important in the management of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - AFFECTS(The management of Systemic Lupus Erythematosus (SLE) is affected by the use of Patient-Reported Outcomes (PROs).) -> Patient-Reported Outcomes (PROs)(Tools used to quantify qualitative information from patients regarding their health status.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - AFFECTS(SLE impacts the Health-Related Quality of Life of patients.) -> Health-Related Quality of Life (HRQoL)(A measure of how well individuals perceive their health and quality of life.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Organ Damage Accrual(The accumulation of damage to organs over time, which was reduced in SLE patients receiving belimumab.) - AFFECTS(EQ-5D Full Health State experience is associated with reduced organ damage accrual in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Ultraviolet Exposure(Exposure to UV radiation, which has been linked to SLE flares.) - AFFECTS(Ultraviolet exposure is associated with flares in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Mortality Risk(The risk of death, which was found to be associated with the Physical Functioning domain in SLE.) - AFFECTS(The Physical Functioning domain of SF-36 is predictive of mortality risk in SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(SLE can lead to kidney involvement, resulting in nephritis.) -> Kidney(An organ that is affected in lupus nephritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(SLE can lead to skin manifestations.) -> Skin(An organ that can be affected by SLE, leading to skin manifestations.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(SLE can lead to joint involvement, resulting in arthritis.) -> Joint(An anatomical structure that can be involved in SLE, leading to arthritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(Fatigue is a symptom of SLE.) -> Fatigue(A common symptom experienced by patients with SLE, impacting their daily life.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - HAS_SYMPTOM(Chronic pain is a symptom of SLE.) -> Chronic Pain(A pervasive symptom for patients with SLE that influences their perception of disease status.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Azathioprine is used in the treatment of SLE.) -> Azathioprine (AZA)(An immunosuppressive drug used in the treatment of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Immunosuppressives are used in the treatment of SLE.) -> Immunosuppressives(Medications used to suppress the immune system in SLE treatment.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Mycophenolate is used in the treatment of SLE.) -> Mycophenolate (MMF)(An immunosuppressive drug used in the treatment of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Methotrexate is used in the treatment of SLE.) -> Methotrexate (MTX)(An immunosuppressive drug used in the treatment of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Hydroxychloroquine is used in the treatment of SLE.) -> Hydroxychloroquine(A medication commonly used in the treatment of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - USED_FOR(Prednisolone is used in the treatment of SLE.) -> Prednisolone(A corticosteroid used to treat inflammation in SLE patients.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Glucocorticoids(A type of medication that may be used in the treatment of SLE, even at low dosages.) - USED_FOR(Glucocorticoids are used in the treatment of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) - RESULTS_IN(Poor management of SLE can lead to organ damage.) -> Organ Damage(A potential outcome of untreated or poorly managed SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "EULAR Guidelines(Recent guidelines for the management of SLE.) - CITES(The EULAR guidelines provide recommendations for SLE management.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Pathophysiology(The study of the functional changes that occur in the body as a result of a disease.) - DESCRIBES(The pathophysiology of SLE is complex and involves multiple factors.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "ACR-1997 Criteria(Criteria established by the American College of Rheumatology for classifying SLE.) - DESCRIBES(The ACR-1997 criteria describe the classification of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "SLICC-2012 Criteria(Criteria established by the Systemic Lupus International Collaborating Clinics for classifying SLE.) - DESCRIBES(The SLICC-2012 criteria describe the classification of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "EULAR/ACR-2019 Criteria(Updated criteria for the classification of SLE established by the European Alliance of Associations for Rheumatology and the American College of Rheumatology.) - DESCRIBES(The EULAR/ACR-2019 criteria describe the classification of SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Detection methods for ANA(Discusses various methods for detecting antinuclear antibodies (ANA) including IIF and ELISA.) - DESCRIBES(The article discusses the condition SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Best Practice & Research Clinical Rheumatology(A scientific article discussing the communication gap between patients and clinicians in Systemic Lupus Erythematosus.) - DESCRIBES(The article discusses the management of Systemic Lupus Erythematosus (SLE).) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Organ-specific damage assessment(Assessing and monitoring organ-specific involvement in SLE patients.) - PART_OF(Organ-specific damage assessment is part of managing SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Low-Disease Activity State(A treatment target defined by specific SLE disease activity index scores.) - TARGETS(A low-disease activity state is a treatment target for SLE.) -> Systemic Lupus Erythematosus (SLE)(An autoimmune disease characterized by the body's immune system attacking its own tissues.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Belimumab(A drug that targets B cells through BLyS/BAFF blockage.) - HAS_EFFECT(Belimumab has an effect on the quality of life of SLE patients.) -> Quality of Life(A measure of the general well-being of individuals.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Belimumab(A drug that targets B cells through BLyS/BAFF blockage.) - USED_FOR(Belimumab is used for treating SLE.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) - PUBLISHED_IN(SLE is discussed in the journal.) -> Best Practice & Research Clinical Rheumatology(A journal focusing on clinical rheumatology research.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "NPSLE(Neuropsychiatric systemic lupus erythematosus, a condition affecting the nervous system.) - ASSOCIATED_WITH(NPSLE is a complication associated with SLE.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Biomarkers(Biological indicators used for diagnosing Systemic Lupus Erythematosus.) - ASSOCIATED_WITH(Biomarkers are associated with diagnosing Systemic Lupus Erythematosus.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) - ASSESSES(Disease activity is a key point in assessing SLE patients.) -> Disease Activity(The level of activity in SLE that needs to be accurately defined.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "EULAR/ACR-2019 SLE classification criteria(Criteria for classifying Systemic Lupus Erythematosus.) - ASSESSES(EULAR/ACR-2019 criteria assess Systemic Lupus Erythematosus.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) - INCLUDES(Patient Reported Outcomes are included in SLE management.) -> Patient Reported Outcomes(Health status evaluations directly reported by the patient.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Cardiovascular Disease(A significant complication of SLE that contributes to morbidity and mortality.) - AFFECTS(Cardiovascular disease is a complication of SLE.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Anifrolumab(A biological therapy used in the treatment of SLE.) - USED_FOR(Anifrolumab is used for treating SLE.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) - RESULTS_IN(Management of SLE aims for better long-term outcomes.) -> Long-term Outcomes(The eventual results of treatment over an extended period.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Missed Diagnosis(Failure to correctly diagnose Systemic Lupus Erythematosus.) - CAUSES(Missed diagnosis can cause issues in identifying Systemic Lupus Erythematosus.) -> SLE(Systemic lupus erythematosus, an autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "DNA Methylation(A process by which methyl groups are added to DNA, affecting gene expression.) - EXPRESSES(Reduced methylation of IL-2 is observed in SLE.) -> IL-2(A cytokine that plays a central role in the regulation of immune responses.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "DNA Methylation(A process by which methyl groups are added to DNA, affecting gene expression.) - EXPRESSES(Increased methylation of FOXP3 is required for regulatory T cell maturation.) -> FOXP3(A transcription factor critical for the development and function of regulatory T cells.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "miR-146a(A microRNA involved in the regulation of immune responses and inflammation.) - LINKED_TO(miR-146a is linked to type-1 interferon gene expression.) -> DNA Methylation(A process by which methyl groups are added to DNA, affecting gene expression.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Rituximab(A second-line treatment used in severe cases of SLE.) - TREATMENT_FOR(Rituximab is used for treating renal lupus, a form of systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - ASSOCIATED_WITH(Immunosuppression is a biological process relevant to the treatment of systemic lupus erythematosus.) -> Immunosuppression(A process aimed at controlling the disease while minimizing susceptibility to infections.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "BILAG and SLEDAI Scoring Systems(Scoring systems used to assess disease activity in SLE.) - DESCRIBES(BILAG and SLEDAI scoring systems describe the disease activity.) -> Disease Activity(The level of activity in SLE that needs to be accurately defined.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Patient Reported Outcomes (PROs)(Tools used to measure patients' perceptions of their health status.) - ASSOCIATED_WITH(PROs are related to the communication gap between patients and clinicians.) -> Communication Gap(The disconnect between patients and clinicians regarding health management.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Clinicians(Healthcare professionals who provide patient care.) - USES(Clinicians use Patient Reported Outcomes to understand patient perspectives.) -> Patient Reported Outcomes (PROs)(Tools used to measure patients' perceptions of their health status.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Antinuclear Antibody (ANA) Testing(A laboratory test used to detect the presence of antinuclear antibodies in the serum.) - LOCATED_IN(ANA testing is performed using HEp-2 cells.) -> HEp-2 Cells(A cell line used in laboratories for the detection of antinuclear antibodies.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Integrate project(A European project focused on integrating patient-driven data into the management of SLE.) - COLLABORATES_WITHCONTRIBUTES_TO(The Rheumatology Unit of Dusseldorf is part of the Integrate project.) -> Rheumatology Unit of Dusseldorf(An organization involved in the Integrate project.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Integrate project(A European project focused on integrating patient-driven data into the management of SLE.) - COLLABORATES_WITHCONTRIBUTES_TO(The Rheumatology Unit of Pisa is part of the Integrate project.) -> Rheumatology Unit of Pisa(An organization involved in the Integrate project.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Integrate project(A European project focused on integrating patient-driven data into the management of SLE.) - COLLABORATES_WITHCONTRIBUTES_TO(The Scuola Superiore Sant’Anna of Pisa is part of the Integrate project.) -> Scuola Superiore Sant’Anna of Pisa(An organization involved in the Integrate project.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Best Practice & Research Clinical Rheumatology(A scientific article discussing the communication gap between patients and clinicians in Systemic Lupus Erythematosus.) - INCLUDES(The article includes a discussion on the role of Patient-Reported Outcomes (PROs).) -> Patient-Reported Outcomes (PROs)(Tools used to quantify qualitative information from patients regarding their health status.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Rheumatologists(Medical professionals specializing in the diagnosis and treatment of rheumatic diseases.) - USES(Rheumatologists use Patient-Reported Outcomes (PROs) to facilitate communication with patients.) -> Patient-Reported Outcomes (PROs)(Tools used to quantify qualitative information from patients regarding their health status.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Communication Gap(The disconnect between patients and clinicians regarding health management.) - CORRELATES_WITH(The communication gap affects the Health-Related Quality of Life.) -> Health-Related Quality of Life (HRQoL)(A measure of how well individuals perceive their health and quality of life.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A severe manifestation of SLE characterized by inflammation of the kidneys.) - LOCATED_IN(Lupus nephritis affects the kidneys.) -> Kidney(An organ that is affected in lupus nephritis.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) - LOCATED_IN(Lupus Nephritis affects the kidneys.) -> Kidney(An organ that is affected in lupus nephritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Fatigue(A common symptom experienced by patients with SLE, impacting their daily life.) - AFFECTS(Fatigue affects the quality of life of patients.) -> Quality of Life (QoL)(An important aspect for patients with SLE, often related to their symptoms and daily functioning.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Chronic Pain(A pervasive symptom for patients with SLE that influences their perception of disease status.) - AFFECTS(Chronic pain affects the quality of life of patients.) -> Quality of Life (QoL)(An important aspect for patients with SLE, often related to their symptoms and daily functioning.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "E. Elefante(An author contributing to the discussion on communication in clinical settings.) - AUTHORED(E. Elefante authored the article discussing communication gaps and PROs.) -> Best Practice & Research Clinical Rheumatology(A scientific article discussing the communication gap between patients and clinicians in Systemic Lupus Erythematosus.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Best Practice & Research Clinical Rheumatology(A scientific article discussing the communication gap between patients and clinicians in Systemic Lupus Erythematosus.) - PUBLISHED_IN(The article is published by Elsevier Ltd.) -> Elsevier Ltd.(The publisher of the article.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Best Practice & Research Clinical Rheumatology(A scientific article discussing the communication gap between patients and clinicians in Systemic Lupus Erythematosus.) - DESCRIBES(The article describes Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - ASSOCIATED_WITH(Lupus nephritis is a condition associated with systemic lupus erythematosus.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - ASSOCIATED_WITH(Anti-DNA antibodies are often present in patients with systemic lupus erythematosus.) -> Anti-DNA Antibodies(Antibodies that are often present in patients with systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - ASSOCIATED_WITH(Lupus genetics refers to the genetic factors associated with systemic lupus erythematosus.) -> Lupus Genetics(The genetic factors associated with systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) - ASSOCIATED_WITH(Lupus Nephritis is a condition associated with Systemic Lupus Erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Anifrolumab(A biological therapy used in the treatment of SLE.) - TREATMENT_FOR(Anifrolumab is proposed for treating systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Benlysta(The first biologic drug approved for the treatment of SLE in the USA.) - TREATMENT_FOR(Benlysta is used as a treatment for systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Atacicept(A drug that blocks two B-cell activation factors, BAFF and APRIL, for SLE treatment.) - TREATMENT_FOR(Atacicept is proposed for treating systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - PRODUCES(Systemic Lupus Erythematosus can lead to the production of Anti-dsDNA Antibodies.) -> Anti-dsDNA Antibodies(Antibodies that are associated with SLE disease activity and can predict the development of lupus nephritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - PRODUCES(Systemic Lupus Erythematosus can lead to the production of Anti-Sm Antibodies.) -> Anti-Sm Antibodies(Antibodies that are characteristic of SLE and serve as a biomarker for SLE classification.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - PRODUCES(Systemic Lupus Erythematosus can lead to the production of Anti-C1q Antibodies.) -> Anti-C1q Antibodies(Antibodies associated with hereditary C1q deficiency and linked to the development of lupus nephritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - EXPRESSES(Systemic lupus erythematosus expresses an interferon signature that helps predict treatment response.) -> Interferon Signature(A biological marker that helps predict response to treatment in SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - HAS_EFFECT(Systemic lupus erythematosus affects the response to treatment.) -> Response to Treatment(The effectiveness of a treatment in managing symptoms of SLE.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - HAS_EFFECT() -> Healthcare Costs(Costs associated with the treatment and management of systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - AFFECTS() -> Immune System Dysfunction(A pathological process involved in systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - AFFECTS(Systemic Lupus Erythematosus affects Health-Related Quality of Life.) -> Health-Related Quality of Life(A measure of the impact of health status on quality of life.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) - HAS_SYMPTOM(Patients experience symptoms due to Systemic Lupus Erythematosus.) -> Patients(Individuals suffering from Systemic Lupus Erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Pharmacogenomics and Personalized Medicine(A journal article discussing treatment approaches for systemic lupus erythematosus (SLE).) - DESCRIBES(The article discusses systemic lupus erythematosus.) -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) - DESCRIBES() -> Systemic Lupus Erythematosus(An autoimmune disease that can affect multiple organ systems.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) - ASSOCIATED_WITH(Both conditions are related to systemic lupus erythematosus.) -> Neuropsychiatric SLE(A group of central and peripheral nervous system syndromes associated with systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Endothelial activation(A process that can lead to complement activation and cellular recruitment in lupus nephritis.) - INVOLVES(Endothelial activation is a process involved in the pathophysiology of lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Type 1 interferons(Cytokines produced by resident and recruited cells in renal lupus associated with damage.) - PRODUCES(Type 1 interferons are produced in renal lupus and are associated with damage.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Anti-dsDNA Antibodies(Antibodies that are associated with SLE disease activity and can predict the development of lupus nephritis.) - AFFECTS(Anti-dsDNA Antibodies can predict the development of Lupus Nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Anti-Sm Antibodies(Antibodies that are characteristic of SLE and serve as a biomarker for SLE classification.) - AFFECTS(Anti-Sm Antibodies are correlated with Lupus Nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Anti-C1q Antibodies(Antibodies associated with hereditary C1q deficiency and linked to the development of lupus nephritis.) - AFFECTS(Anti-C1q Antibodies are correlated with Lupus Nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Afro-Caribbean patients(A demographic group that is more likely to develop lupus nephritis.) - AFFECTS(Afro-Caribbean patients are more likely to develop lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) - HAS_SYMPTOM(Podocyte injury is a significant symptom in lupus nephritis.) -> Podocyte injury(Damage to podocytes that correlates with proteinuria and renal outcome in lupus nephritis.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "International Society of Nephrology/Renal Pathology Society(An organization that classifies glomerulonephritis based on glomerular lesions.) - CLASSIFIES(The organization classifies glomerulonephritis, including lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) - RESULTS_IN(Lupus nephritis can lead to end-stage renal disease.) -> End-stage renal disease(A final stage of chronic kidney disease resulting from various kidney injuries.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "B cells(A type of lymphocyte that produces antibodies.) - ACTIVATES(B cells are activated in the renal parenchyma during lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Vascular lesions(Commonly observed lesions in lupus nephritis biopsies that correlate with renal outcome.) - OBSERVED_IN(Vascular lesions are commonly observed in lupus nephritis biopsies.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Proliferative GN(A classification of glomerulonephritis that includes focal and diffuse types.) - PART_OF(Proliferative GN is a classification that includes lupus nephritis.) -> Lupus Nephritis(A significant glomerulonephritis that develops in patients with systemic lupus erythematosus (SLE), leading to morbidity and mortality.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Anifrolumab(A biological therapy used in the treatment of SLE.) - HAS_EFFECT(Anifrolumab shows functional improvement in SLE patients.) -> Functional Improvement(Enhancement in the ability to perform daily activities.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Vital and colleagues(Researchers who identified two signatures related to interferon genes in predicting treatment response.) - COLLABORATES_WITHCONTRIBUTES_TO(Vital and colleagues contributed to the understanding of interferon signatures in predicting treatment response.) -> Interferon Signature(A biological marker that helps predict response to treatment in SLE.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "TWEAK(A pro-inflammatory cytokine that binds to its receptor Fn14, involved in predicting response to induction therapy in lupus nephritis.) - INTERACTS_WITH(TWEAK interacts with treatment response in lupus nephritis.) -> Response to Treatment(The effectiveness of a treatment in managing symptoms of SLE.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Lupus Europe(An organization focused on improving the lives of people with lupus.) - COLLABORATES_WITHCONTRIBUTES_TO(Lupus Europe collaborates to improve the lives of patients with Systemic Lupus Erythematosus.) -> Patients(Individuals suffering from Systemic Lupus Erythematosus.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Physicians(Medical professionals who treat patients with Systemic Lupus Erythematosus.) - ASSESSES(Physicians assess the condition of patients with Systemic Lupus Erythematosus.) -> Patients(Individuals suffering from Systemic Lupus Erythematosus.) [sourced from: truncated-pdfs/GAP-between-patients-and-clinicians_2023_Best-Practice-trunc.pdf]\n",
      "====\n",
      "Haitao Yu(One of the authors of the review article.) - AUTHORED() -> Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Yasuo Nagafuchi(One of the authors of the review article.) - AUTHORED() -> Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Keishi Fujio(One of the authors of the review article.) - AUTHORED() -> Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) - PUBLISHED_IN() -> MDPI(The publisher of the review article.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus(A review article discussing biomarkers for diagnosing and monitoring systemic lupus erythematosus (SLE).) - INCLUDES() -> Clinical and Immunological Biomarkers(Indicators that could help diagnose and monitor disease activity in systemic lupus erythematosus.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Omics Approaches(Techniques used to reveal new biomarkers for SLE.) - INCLUDES(Omics approaches include analysis of B cells.) -> B cells(A type of lymphocyte that produces antibodies.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "B cells(A type of lymphocyte that produces antibodies.) - EXPRESSES(B cells that secrete IL-10 are functionally impaired in SLE.) -> IL-10(A regulatory cytokine that modulates immune responses.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "B cells(A type of lymphocyte that produces antibodies.) - EXPRESSES(B cells may be influenced by BLyS, which affects their survival.) -> BLyS(A cytokine that promotes B cell survival and differentiation.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf, truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Epigenetic alterations(Changes in gene expression regulation that can influence disease pathogenesis.) - PARTICIPATES_IN(Epigenetic differences are observed in B cell subsets in SLE patients.) -> B cells(A type of lymphocyte that produces antibodies.) [sourced from: truncated-pdfs/biomolecules-11-00928-v2-trunc.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing the complexities of systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED(Elliott Lever is one of the authors of the article.) -> Elliott Lever(One of the authors of the article.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing the complexities of systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED(Marta R Alves is one of the authors of the article.) -> Marta R Alves(One of the authors of the article.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing the complexities of systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - AUTHORED(David A Isenberg is one of the authors of the article.) -> David A Isenberg(One of the authors of the article.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n",
      "====\n",
      "Towards Precision Medicine in Systemic Lupus Erythematosus(A review article discussing the complexities of systemic lupus erythematosus (SLE) and the challenges in applying precision medicine.) - PUBLISHED_IN(The article was published in this journal.) -> Pharmacogenomics and Personalized Medicine(The journal in which the article was published.) [sourced from: truncated-pdfs/pgpm-13-39-trunc.pdf]\n"
     ]
    }
   ],
   "execution_count": 13
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:56:31.473660Z",
     "start_time": "2024-10-07T20:56:31.461139Z"
    }
   },
   "cell_type": "code",
   "source": "len(vc_res.records)",
   "id": "750f7fa9b7112ba7",
   "outputs": [
    {
     "data": {
      "text/plain": [
       "174"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "execution_count": 14
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": [
    "## GraphRAG Pipelines\n",
    " You can construct GraphRAG pipelines with the `GraphRAG` class.  At minimum, you will need to pass the constructor an LLM and a retriever. You can also pass a custom prompt template, but for now we will just use the default.\n",
    " "
   ],
   "id": "f2e55b8b3511cf1"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T20:56:32.941166Z",
     "start_time": "2024-10-07T20:56:32.901516Z"
    }
   },
   "cell_type": "code",
   "source": [
    "from neo4j_graphrag.llm import OpenAILLM as LLM\n",
    "from neo4j_graphrag.generation.graphrag import GraphRAG\n",
    "\n",
    "llm = LLM(model_name=\"gpt-4o\",  model_params={\"temperature\": 0})\n",
    "\n",
    "v_rag  = GraphRAG(llm=llm, retriever=vector_retriever)\n",
    "vc_rag = GraphRAG(llm=llm, retriever=vc_retriever)"
   ],
   "id": "8e2cf317a83d59ae",
   "outputs": [],
   "execution_count": 15
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T21:01:05.023955Z",
     "start_time": "2024-10-07T21:00:54.308303Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Can you summarize systemic lupus erythematosus (SLE)? including common effects, biomarkers for identifying, treatments, and current challenges facing faced by Physicians and patients? Provide in list format\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "fc00036185900e97",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "Certainly! Here's a summary of systemic lupus erythematosus (SLE) including its common effects, biomarkers for identifying, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "1. **Common Effects of SLE:**\n",
      "   - SLE is a systemic autoimmune disease characterized by immune system dysfunction.\n",
      "   - It presents with a wide range of clinical manifestations, including renal, dermatological, neuropsychiatric, and cardiovascular symptoms.\n",
      "   - Patients often experience fatigue, pain, and limitations in daily life activities.\n",
      "\n",
      "2. **Biomarkers for Identifying SLE:**\n",
      "   - Clinical and immunological biomarkers are critical for diagnosing and monitoring SLE.\n",
      "   - Biomarkers help in assessing pathophysiological processes and disease activity.\n",
      "   - Novel biomarkers have been discovered through \"omics\" research, although many lack sufficient sensitivity, specificity, or predictive power for clinical use.\n",
      "\n",
      "3. **Treatments for SLE:**\n",
      "   - The treatment approach is multidisciplinary, focusing on controlling symptoms and delaying disease progression.\n",
      "   - Long-term therapies are required, and patients must manage side effects and potential risks associated with treatments.\n",
      "   - There is no complete cure for SLE, and treatment aims to improve quality of life.\n",
      "\n",
      "4. **Current Challenges:**\n",
      "   - **For Physicians:**\n",
      "     - There is a discordance between physician and patient perspectives on disease management.\n",
      "     - Physicians focus on preventing organ damage, while patients prioritize symptoms affecting daily life.\n",
      "     - There is a need for more robust biomarkers and advanced computational methods to analyze large datasets.\n",
      "   - **For Patients:**\n",
      "     - Patients face challenges in understanding the significance of laboratory alterations and clinical manifestations.\n",
      "     - Fatigue and chronic pain are pervasive symptoms that significantly impact patients' perception of disease status.\n",
      "     - Communication gaps exist between patients and physicians, affecting the management of the disease.\n",
      "\n",
      "Overall, SLE remains a significant social and public health problem, with ongoing research needed to improve diagnosis, treatment, and patient-physician communication.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Certainly! Here's a summary of systemic lupus erythematosus (SLE) including its common effects, biomarkers for identification, treatments, and current challenges faced by physicians and patients:\n",
      "\n",
      "**Common Effects of SLE:**\n",
      "- Affects multiple organ systems, including skin, joints, kidneys, and the nervous system.\n",
      "- Symptoms include nephritis, skin manifestations, arthritis, fatigue, and chronic pain.\n",
      "- Can lead to organ damage if poorly managed.\n",
      "- Impacts health-related quality of life (HRQoL).\n",
      "\n",
      "**Biomarkers for Identifying SLE:**\n",
      "- Anti-dsDNA antibodies: Associated with disease activity and lupus nephritis.\n",
      "- Anti-Sm antibodies: Serve as a biomarker for SLE classification.\n",
      "- Anti-C1q antibodies: Linked to the development of lupus nephritis.\n",
      "- Antinuclear Antibody (ANA) testing: High sensitivity but relatively low specificity for SLE.\n",
      "- Interferon signature: Helps predict response to treatment.\n",
      "\n",
      "**Treatments for SLE:**\n",
      "- Immunosuppressants (e.g., Azathioprine, Mycophenolate, Methotrexate).\n",
      "- Antimalarials (e.g., Hydroxychloroquine).\n",
      "- Glucocorticoids (e.g., Prednisolone).\n",
      "- Biologic therapies (e.g., Belimumab, Anifrolumab).\n",
      "- Rituximab: Used for B cell depletion in severe cases.\n",
      "- Cyclophosphamide: Used for severe life-threatening lupus.\n",
      "\n",
      "**Current Challenges:**\n",
      "- Communication gap between patients and clinicians affects management and HRQoL.\n",
      "- High healthcare costs associated with treatment and management.\n",
      "- Need for accurate assessment of disease activity and organ-specific damage.\n",
      "- Balancing immunosuppression to control disease while minimizing infection risk.\n",
      "- Managing patient-reported outcomes (PROs) to improve treatment response and quality of life.\n",
      "\n",
      "These points provide a comprehensive overview of SLE, highlighting its complexity and the multifaceted approach required for effective management.\n"
     ]
    }
   ],
   "execution_count": 19
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Lets start with  simple question and compare the answers for each",
   "id": "e772c5de32ef9bda"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T21:03:40.902406Z",
     "start_time": "2024-10-07T21:03:30.633538Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"What organ systems are most commonly affected by lupus? and how are they treated? provide in list format\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "477f00c916132357",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "1. **Skin**: \n",
      "   - Treatment: Topical and oral steroids, hydroxychloroquine. Severe cases may require rituximab.\n",
      "\n",
      "2. **Renal (Kidneys)**:\n",
      "   - Treatment: High-dose steroids, cyclophosphamide, mycophenolate mofetil (MMF), or azathioprine.\n",
      "\n",
      "3. **Neuropsychiatric (Cerebral)**:\n",
      "   - Treatment: High-dose steroids and immunosuppressive agents like cyclophosphamide.\n",
      "\n",
      "4. **Musculoskeletal (Polyarthritis)**:\n",
      "   - Treatment: Hydroxychloroquine, corticosteroids, methotrexate.\n",
      "\n",
      "5. **Hematological (Thrombocytopenia)**:\n",
      "   - Treatment: Corticosteroids, hydroxychloroquine, azathioprine, or mycophenolate mofetil.\n",
      "\n",
      "6. **Cardiovascular (Lupus Antiphospholipid Syndrome - APS)**:\n",
      "   - Treatment: Anticoagulation therapy such as warfarin or low molecular weight heparin (LMWH).\n",
      "\n",
      "7. **Pulmonary (Pleurisy/Pericarditis)**:\n",
      "   - Treatment: Corticosteroids and immunosuppressive agents.\n",
      "\n",
      "8. **Gastrointestinal**:\n",
      "   - Treatment: Not specifically captured in SLEDAI scoring, but managed based on symptoms and severity.\n",
      "\n",
      "Note: Treatment varies based on the severity of the disease and may include additional immunosuppressive agents or biologics like rituximab or belimumab for more severe cases.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "The organ systems most commonly affected by lupus (Systemic Lupus Erythematosus, SLE) and their treatments include:\n",
      "\n",
      "1. **Kidneys (Lupus Nephritis)**\n",
      "   - **Treatment:** \n",
      "     - Cyclophosphamide\n",
      "     - Rituximab\n",
      "     - Mycophenolate (MMF)\n",
      "     - Azathioprine (AZA)\n",
      "     - Prednisolone\n",
      "     - Anifrolumab\n",
      "\n",
      "2. **Skin**\n",
      "   - **Treatment:**\n",
      "     - Hydroxychloroquine\n",
      "     - Glucocorticoids\n",
      "\n",
      "3. **Joints (Arthritis)**\n",
      "   - **Treatment:**\n",
      "     - Methotrexate (MTX)\n",
      "     - Glucocorticoids\n",
      "\n",
      "4. **Immune System**\n",
      "   - **Treatment:**\n",
      "     - Belimumab\n",
      "     - Atacicept\n",
      "     - Anifrolumab\n",
      "\n",
      "5. **Nervous System (Neuropsychiatric SLE)**\n",
      "   - **Treatment:**\n",
      "     - Rituximab (for severe cases)\n",
      "\n",
      "6. **General Inflammation and Autoimmune Activity**\n",
      "   - **Treatment:**\n",
      "     - Antimalarials\n",
      "     - Glucocorticoids\n",
      "     - Immunosuppressants\n",
      "\n",
      "These treatments aim to manage symptoms, reduce inflammation, and prevent organ damage associated with lupus.\n"
     ]
    }
   ],
   "execution_count": 22
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "Now lets try a bit more of a complex question",
   "id": "27fc4a28eec0d800"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T17:49:28.589181Z",
     "start_time": "2024-10-07T17:49:22.569015Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"How does precision medicine help in treating systemic lupus erythematosus (SLE)?\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q).answer}\")"
   ],
   "id": "52bf2c3383f67352",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "Precision medicine in treating systemic lupus erythematosus (SLE) involves tailoring treatment to individual patients based on their genetic and epigenetic characteristics, which influence disease pathophysiology and drug response. This approach aims to optimally assess SLE patients, predict disease course, and determine treatment response at diagnosis. Ideally, each patient would undergo an initial evaluation to profile their disease, assess the main pathophysiologic pathway through biomarkers, predict the risk of specific organ damage, and identify the most suitable treatment. This would allow for better follow-up and flare prediction. Although there is exciting potential for improving precision in lupus care, achieving this goal universally in the short term is unlikely. Current treatments are individualized to some extent based on organ involvement, with the primary objective being remission of disease signs and symptoms to prevent organ damage. However, the development of biologic drugs capable of targeting individual molecules is expected to provide a more precise approach to SLE treatment in the future.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Precision medicine helps in treating systemic lupus erythematosus (SLE) by allowing for a more tailored approach to treatment based on individual patient characteristics. This approach considers genetic, environmental, and lifestyle factors that influence disease progression and response to treatment. By understanding the specific pathophysiology and biomarkers associated with an individual's SLE, healthcare providers can select the most effective therapies, minimize side effects, and improve overall disease management. Precision medicine aims to optimize treatment outcomes by considering the unique aspects of each patient's condition.\n"
     ]
    }
   ],
   "execution_count": 33
  },
  {
   "metadata": {},
   "cell_type": "markdown",
   "source": "",
   "id": "461dad8755e55348"
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T21:05:14.001373Z",
     "start_time": "2024-10-07T21:04:57.992439Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Which biomarkers are associated with predicting organ damage in lupus patients? - provide a detailed list\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "b72a4184409b68ea",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "Biomarkers associated with predicting organ damage in lupus patients include:\n",
      "\n",
      "1. **Lupus Nephritis (LN):**\n",
      "   - **Anti-dsDNA antibodies (Serum):** Associated with SLE disease activity and can predict the development of LN. High specificity (96%) but low diagnostic sensitivity (52–70%).\n",
      "   - **Anti-Sm antibodies (Serum):** Correlates with SLE disease activity and LN. Highly specific diagnostic biomarker for SLE with a specificity of 99% but low sensitivity (5–30%). High titers predict silent LN and early poor outcomes in LN.\n",
      "   - **Anti-C1q antibodies (Serum):** Increased titers predict renal flares in LN with 81–97% sensitivity and 71–95% specificity. Absence of anti-C1q is associated with a nearly 100% negative predictive value for LN development.\n",
      "   - **Proteinuria; Protein/creatinine ratio; 24-h urine protein (Urine):** Conventional urinary biomarkers for LN.\n",
      "   - **Chemokines and Cytokines (Urine):** Evaluated as potential SLE biomarkers, but few have been independently validated.\n",
      "   - **Angiopoetin-like 4; L-selectin; TGF-β1 (Urine):** Biomarker candidates for tracking disease activity in LN.\n",
      "\n",
      "2. **Skin Lesions:**\n",
      "   - **AhR ratio (Serum):** Associated with SLE activity and may be an independent risk factor for skin lesions in SLE.\n",
      "   - **Anti-SSA antibodies (Serum):** Associated with subacute cutaneous lupus.\n",
      "   - **VGLL-3 (Serum):** Leads to cutaneous lupus.\n",
      "\n",
      "3. **Neuropsychiatric Systemic Lupus Erythematosus (NPSLE):**\n",
      "   - **Lupus anticoagulant antibodies; Anticardiolipin antibodies; Anti-β2-glycoprotein I antibodies (Serum or CSF):** Associated with NPSLE manifestations; diagnostic biomarkers of NPSLE.\n",
      "   - **Anti-RibP (Serum or CSF):** Highly specific biomarker in the diagnosis of SLE and associated with NPSLE.\n",
      "   - **Anti-U1 ribonucleoprotein antibodies (Serum or CSF):** Elevated in CSF and sera of NPSLE patients; might cause NPSLE.\n",
      "   - **Anti-NMDAR (CSF):** Associated with central nervous system manifestations of NPSLE.\n",
      "   - **IL-6, 8, 10, TNF-a; IFN-γ; MCP-1; IP-10 (CSF):** Associated with NPSLE.\n",
      "\n",
      "4. **Cardiovascular Disease (CVD):**\n",
      "   - **LHR; MHR (Serum):** Predicts CVD risk in SLE patients, even at the onset of disease.\n",
      "   - **Cardiac troponin T (Serum):** Independently associated with incident cardiovascular events in SLE patients.\n",
      "   - **Paraoxonase 1 and HDL (Serum):** Key biomarker of accelerated atherosclerosis in lupus and may serve as a potential therapeutic biomarker for SLE patients with CVD.\n",
      "   - **IgG-anticardiolipin antibodies; E-selectin (Serum):** Associated with CVD in SLE and correlated with disease activity. \n",
      "\n",
      "These biomarkers help in diagnosing, monitoring, and predicting the progression of organ-specific damage in lupus patients.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "In lupus patients, several biomarkers are associated with predicting organ damage. Here is a detailed list:\n",
      "\n",
      "1. **Anti-dsDNA Antibodies**: These antibodies are associated with systemic lupus erythematosus (SLE) disease activity and can predict the development of lupus nephritis, which is a significant cause of organ damage.\n",
      "\n",
      "2. **Anti-Sm Antibodies**: These are highly specific diagnostic biomarkers for SLE and correlate with SLE disease activity and lupus nephritis, contributing to organ damage.\n",
      "\n",
      "3. **Anti-C1q Antibodies**: Increased titers of these antibodies predict renal flares in lupus nephritis, which can lead to organ damage.\n",
      "\n",
      "4. **Paraoxonase 1 and HDL**: These are key biomarkers of accelerated atherosclerosis in lupus, which can lead to cardiovascular organ damage.\n",
      "\n",
      "5. **Cardiac Troponin T**: This biomarker is independently associated with incident cardiovascular events in SLE patients, indicating potential cardiovascular organ damage.\n",
      "\n",
      "6. **CVDLHR (Cardiovascular Disease Lupus Health Risk)**: This predicts cardiovascular disease risk in SLE patients, which can result in organ damage.\n",
      "\n",
      "7. **Angiopoetin-like 4**: This is a biomarker candidate for tracking disease activity in lupus nephritis, which can lead to kidney damage.\n",
      "\n",
      "These biomarkers help in assessing the risk and progression of organ damage in lupus patients, allowing for more targeted and effective management of the disease.\n"
     ]
    }
   ],
   "execution_count": 24
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T21:05:59.464225Z",
     "start_time": "2024-10-07T21:05:42.714829Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"How are the kidneys affected by Lupus? - provide a detailed list\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':1}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':1}).answer}\")"
   ],
   "id": "75d74652342b2d4f",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "Lupus can significantly affect the kidneys, leading to a condition known as lupus nephritis (LN). Here is a detailed list of how the kidneys are affected:\n",
      "\n",
      "1. **Glomerulonephritis (GN):** Up to 50% of SLE patients develop clinically significant GN, which is a major cause of morbidity and mortality. GN involves inflammation of the glomeruli, the filtering units of the kidney.\n",
      "\n",
      "2. **Classification of GN:** The International Society of Nephrology/Renal Pathology Society (ISN/RPS) classifies GN into different classes based on glomerular lesions:\n",
      "   - **Class I and II:** Mesangial nephritis with a better prognosis due to the high regenerative capacity of mesangial cells.\n",
      "   - **Class III (Focal) and IV (Diffuse):** Proliferative GN with subendothelial deposition of immune complexes (ICs) in glomerular capillaries, leading to endothelial activation and germinal center formation.\n",
      "   - **Class V:** Membranous IC deposition in the subepithelial space, causing local inflammation and podocyte damage.\n",
      "\n",
      "3. **Tubulointerstitial Inflammation:** This does not always co-exist with glomerular lesions, but its severity correlates better with renal outcomes. Tubulointerstitial injuries are significant in LN patients.\n",
      "\n",
      "4. **Endothelial Activation:** Direct damage or reactive oxygen species (ROS) cause complement activation and cellular recruitment, contributing to LN.\n",
      "\n",
      "5. **Immune Complexes and Autoantibodies:** These aggregate along the tubular basement membrane and bind podocytes, potentially involving free DNA from defective NETosis.\n",
      "\n",
      "6. **MicroRNAs:** Dysregulation of microRNAs can lead to podocyte cytoskeleton issues and deficiencies in E-cadherin and intercellular adhesion.\n",
      "\n",
      "7. **Podocyte Injury:** Correlates with the degree of proteinuria and renal outcome. Morphologically similar to minimal change disease or focal segmental glomerulosclerosis (FSGS).\n",
      "\n",
      "8. **Vascular Lesions:** Include vascular immune IC deposits, arteriosclerosis, thrombotic microangiopathy (TMA), non-inflammatory necrotizing vasculopathy, and true renal vasculitis. These lesions correlate with renal outcomes and disease activity.\n",
      "\n",
      "9. **Chronic Inflammation:** Leads to cell death, cellular regeneration, and fibrosis, resulting in glomerulosclerosis and potentially end-stage renal disease.\n",
      "\n",
      "Overall, lupus nephritis involves a complex network of immune and inflammatory processes that can severely damage the kidneys.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "Lupus, specifically Systemic Lupus Erythematosus (SLE), can significantly affect the kidneys, leading to a condition known as Lupus Nephritis. Here is a detailed list of how the kidneys are affected:\n",
      "\n",
      "1. **Inflammation**: Lupus Nephritis is characterized by inflammation of the kidneys, which can lead to damage and impaired kidney function.\n",
      "\n",
      "2. **Glomerulonephritis**: This is a specific type of kidney inflammation that affects the glomeruli, the filtering units of the kidneys. Lupus Nephritis is a significant form of glomerulonephritis.\n",
      "\n",
      "3. **Podocyte Injury**: Damage to podocytes, which are cells in the kidneys that help filter blood, is a significant symptom in lupus nephritis. This injury correlates with proteinuria (excess protein in urine) and can affect renal outcomes.\n",
      "\n",
      "4. **Vascular Lesions**: These are commonly observed in lupus nephritis biopsies and correlate with renal outcomes. They indicate damage to the blood vessels within the kidneys.\n",
      "\n",
      "5. **Endothelial Activation**: This process can lead to complement activation and cellular recruitment, contributing to the pathophysiology of lupus nephritis.\n",
      "\n",
      "6. **Type 1 Interferons**: These cytokines are produced in renal lupus and are associated with kidney damage.\n",
      "\n",
      "7. **Progression to End-Stage Renal Disease**: Lupus nephritis can lead to end-stage renal disease, which is the final stage of chronic kidney disease resulting from various kidney injuries.\n",
      "\n",
      "8. **Presence of Autoantibodies**: Anti-dsDNA, Anti-Sm, and Anti-C1q antibodies are associated with lupus nephritis and can predict its development.\n",
      "\n",
      "9. **Demographic Susceptibility**: Certain demographic groups, such as Afro-Caribbean patients, are more likely to develop lupus nephritis.\n",
      "\n",
      "These effects highlight the severe impact lupus can have on kidney health, necessitating careful monitoring and management in affected individuals.\n"
     ]
    }
   ],
   "execution_count": 25
  },
  {
   "metadata": {
    "ExecuteTime": {
     "end_time": "2024-10-07T18:30:27.255660Z",
     "start_time": "2024-10-07T18:30:16.589736Z"
    }
   },
   "cell_type": "code",
   "source": [
    "q = \"Which clinical biomarkers are relevant to both adults and children with systemic lupus erythematosus, and how do treatment approaches differ based on these biomarkers?\"\n",
    "print(f\"\\n\\nVector Response: \\n{v_rag.search(q, retriever_config={'top_k':3}).answer}\")\n",
    "print(f\"\\n\\nVector + Cypher Response: \\n{vc_rag.search(q, retriever_config={'top_k':3}).answer}\")"
   ],
   "id": "ee1393f3bc6e16e8",
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "\n",
      "Vector Response: \n",
      "The context provided does not specifically differentiate between clinical biomarkers relevant to adults and children with systemic lupus erythematosus (SLE). However, it does list several biomarkers associated with SLE and its manifestations, such as lupus nephritis (LN), skin lesions, and neuropsychiatric SLE (NPSLE). These biomarkers include:\n",
      "\n",
      "1. **Anti-dsDNA antibodies**: Associated with SLE disease activity and can predict the development of LN.\n",
      "2. **Anti-Sm antibodies**: Correlate with SLE disease activity and LN.\n",
      "3. **Anti-C1q antibodies**: Predict renal flares in LN.\n",
      "4. **Proteinuria and urine protein/creatinine ratio**: Conventional urinary biomarkers for LN.\n",
      "5. **Chemokines and cytokines in urine**: Evaluated as potential SLE biomarkers.\n",
      "6. **AhR ratio**: Associated with SLE activity and skin lesions.\n",
      "7. **Anti-SSA antibodies**: Associated with subacute cutaneous lupus.\n",
      "8. **Antiphospholipid antibodies**: Associated with NPSLE manifestations.\n",
      "9. **Anti-NMDAR antibodies**: Associated with central nervous system manifestations of NPSLE.\n",
      "\n",
      "Treatment approaches in SLE may differ based on these biomarkers, as they can indicate disease activity, predict flares, and help in diagnosing specific manifestations of SLE. For instance, the presence of anti-dsDNA antibodies might lead to more aggressive treatment to prevent renal involvement, while anti-NMDAR antibodies might guide treatment decisions in NPSLE. However, the context does not provide specific treatment differences based on these biomarkers for adults versus children.\n",
      "\n",
      "\n",
      "Vector + Cypher Response: \n",
      "In both adults and children with systemic lupus erythematosus (SLE), several clinical biomarkers are relevant, including:\n",
      "\n",
      "1. **Anti-dsDNA antibodies**: These are associated with SLE disease activity and can predict the development of lupus nephritis.\n",
      "2. **Anti-Sm antibodies**: These are highly specific diagnostic biomarkers for SLE and correlate with lupus nephritis.\n",
      "3. **Anti-C1q antibodies**: These predict renal flares in lupus nephritis and correlate with active lupus nephritis.\n",
      "4. **Antinuclear Antibody (ANA)**: A biomarker used in the classification of SLE.\n",
      "5. **Double-stranded DNA (dsDNA) Antibodies**: Used for categorizing nephritis compatible with SLE.\n",
      "6. **Anticardiolipin Antibodies**: Added to the immunologic criteria for SLE.\n",
      "7. **Complement Proteins**: Included in the EULAR/ACR-2019 SLE classification criteria.\n",
      "8. **SLE-specific Antibodies**: Included in the EULAR/ACR-2019 SLE classification criteria.\n",
      "9. **Antiphospholipid Antibodies**: Included in the EULAR/ACR-2019 SLE classification criteria.\n",
      "\n",
      "Treatment approaches for SLE can differ based on these biomarkers. For instance, the presence of specific antibodies like anti-dsDNA or anti-Sm may indicate a higher risk of lupus nephritis, leading to more aggressive treatment strategies, including immunosuppressive therapies. In contrast, the presence of antiphospholipid antibodies may necessitate anticoagulation therapy to prevent thrombotic events.\n",
      "\n",
      "In children with SLE, known as childhood systemic lupus erythematosus (cSLE), the disease often presents more severely, and treatment may require a more aggressive approach. This can include higher doses of corticosteroids or the use of additional immunosuppressive agents to control disease activity and prevent organ damage.\n",
      "\n",
      "Overall, the treatment of SLE is highly individualized, taking into account the specific biomarkers present, the severity of the disease, and the organs involved. Long-term immunosuppressive treatment is often required for many patients due to persistently active disease.\n"
     ]
    }
   ],
   "execution_count": 41
  },
  {
   "metadata": {},
   "cell_type": "code",
   "outputs": [],
   "execution_count": null,
   "source": "",
   "id": "10da6c2392802506"
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
